Scholars@Duke
Robert John Mentz

Robert John Mentz

Associate Professor of Medicine
Medicine, Cardiology
robert.mentz@duke.edu
NP-8062, DCRI. PO Box 17969, Durham, NC 27715
NP-8062, DCRI. PO Box 17969, Durham, NC 27715

Scholarly Works - Journal articles

Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial.

Journal article Am Heart J · November 2026 BACKGROUND: Loop diuretics are widely used for managing congestion in patients with heart failure (HF). The TRANSFORM-HF trial is a multicenter randomized study that enrolled heart failure patients, comparing a strategy of torsemide vs furosemide. The time ... Full text Link to item Cite

Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis.

Journal article Eur Heart J Qual Care Clin Outcomes · September 16, 2026 AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a foundational therapeutic option for type 2 diabetes mellitus (T2DM), offering glycaemic control and cardiovascular benefits. This systematic review and meta-analysis evaluate the ... Full text Link to item Cite

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

Journal article Eur J Heart Fail · September 8, 2026 BACKGROUND AND AIMS: It is uncertain whether the effect of vericiguat varies across levels of background guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF). METHODS: We conducted an exploratory analysis of VIC ... Full text Link to item Cite

Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.

Journal article Am Heart J · September 2026 BACKGROUND: In the EXSCEL trial, exenatide did not reduce major adverse cardiovascular events (MACE), but heterogeneity of benefit and the role of cardiac biomarkers remain uncertain. We evaluated the prognostic value of baseline and 1-year changes in N-te ... Full text Link to item Cite

Device-based therapies for cardiorenal syndrome: A comprehensive, mechanism-driven framework for next-generation decongestion.

Journal article Eur J Intern Med · September 2026 BACKGROUND: Cardiorenal dysfunction is a major contributor to morbidity, rehospitalization, and mortality in advanced heart failure (HF) and cardiogenic shock. Traditional decongestive approaches-loop diuretics, combination natriuretics, and ultrafiltratio ... Full text Link to item Cite

A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.

Journal article JCI Insight · August 24, 2026 BACKGROUNDAdults with type 2 diabetes mellitus (T2DM) are at increased risk for stroke, myocardial infarction, and cardiovascular death, yet individual risk is heterogeneous and incompletely captured by clinical models.METHODSIn the Exenatide Study of Card ... Full text Link to item Cite

Lost to Follow-Up in Pragmatic Trials With Remote Follow-Up: Insights From CONNECT-HF and TRANSFORM-HF.

Journal article J Am Heart Assoc · August 4, 2026 BACKGROUND: Pragmatic trials commonly use remote follow-up to reduce participant burden and costs. However, these approaches may increase the risk of lost to follow-up (LTFU). We identified patient- and site-level factors associated with LTFU in 2 large, p ... Full text Link to item Cite

Cardiovascular Multimorbidity and Associated Mortality Among Medicare Beneficiaries Dually Eligible for Medicaid.

Journal article J Am Heart Assoc · August 4, 2026 BACKGROUND: Patients dually eligible for Medicare and Medicaid have higher mortality rates and disparate outcomes for acute cardiovascular conditions compared with those eligible for Medicare alone. However, the association between dual eligibility, cardio ... Full text Link to item Cite

Trends in Cardiac Arrest Mortality Among Young Adults in the United States, 1999 to 2024.

Journal article JACC Adv · August 2026 BACKGROUND: Cardiac arrest (CA) affecting young individuals has been identified as a public health concern in the United States. OBJECTIVES: This study analyzes mortality trends associated with CA in young adults in the United States, focusing on demograph ... Full text Link to item Cite

Embracing Uncertainty.

Journal article J Card Fail · August 2026 Full text Link to item Cite

Ironing Out the Details: Advancing Diagnosis and Treatment of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction - A Narrative Review.

Journal article Heart Fail Rev · July 15, 2026 Iron deficiency (ID) is a highly prevalent and clinically significant comorbidity in heart failure with preserved ejection fraction (HFpEF), affecting 40-60% of patients. Independent of anemia, ID is associated with reduced exercise capacity, diminished qu ... Full text Link to item Cite

Characterizing real-world use of vericiguat in the United States.

Journal article J Card Fail · July 2026 BACKGROUND: Contemporary data regarding uptake of vericiguat for treatment of heart failure (HF), including achievement of target dose (10 mg), are lacking. METHODS: A retrospective analysis of TriNetX claims data was conducted. The study included US adult ... Full text Link to item Cite

Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale.

Journal article Am Heart J · July 2026 RATIONALE: Older patients hospitalized for acute decompensated heart failure with preserved ejection fraction (HFpEF) experience persistently poor outcomes, including physical disability, cognitive impairment, depression, impaired health-related quality of ... Full text Link to item Cite

Diuretic Resistance Risk and the Efficacy of Torsemide vs Furosemide: A Post-Hoc Analysis of the TRANSFORM-HF Trial.

Journal article Eur J Heart Fail · June 25, 2026 BACKGROUND/AIMS: Among hospitalized patients with HF, diuretic resistance is associated with residual congestion, poor health status, and increased risk of HF hospitalization and mortality in the post-discharge period. The TRANSFORM-HF trial demonstrated n ... Full text Link to item Cite

Palliative Care in Advanced Heart Failure.

Journal article Curr Heart Fail Rep · June 4, 2026 PURPOSE OF REVIEW: Advanced heart failure (HF) is characterized by high symptom burden, poor quality of life (QoL), and recurrent hospitalizations. As survival improves, an increasing proportion of patients progresses to advanced stages, leading to a growi ... Full text Link to item Cite

Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Journal article Kidney Int · June 2026 Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, which elevates the risks of hospitalization, disease progression, and death. Despite advances in treating each condition independently, many challenges remain in diagnosing and managin ... Full text Link to item Cite

Implementation of a Digital Patient Activation Tool to Engage Patients With Heart Failure in Intensification of Guideline-Directed Medical Therapies.

Journal article Comput Inform Nurs · June 1, 2026 Heart failure with reduced ejection fraction treatment with quadruple therapy reduces hospitalizations and improves patient survival. Despite evidence-based recommendations to initiate and up-titrate guideline-directed medical therapy to target doses, a ga ... Full text Link to item Cite

Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.

Journal article NEJM Evid · June 2026 BACKGROUND: Prior analyses of trials comparing direct oral anticoagulants (DOACs) to warfarin in atrial fibrillation (AF) have not routinely incorporated patient preferences, despite substantial variation in how patients value the trade-off between outcome ... Full text Link to item Cite

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.

Journal article Future Cardiol · June 2026 Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF). Treatment with intravenous (IV) iron is recommended by the ACC/AHA/HFSA and ESC guidelines to improve HF symptoms, exercise capacity, and quality of life, and to reduce the r ... Full text Link to item Cite

Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America.

Journal article J Card Fail · May 9, 2026 Cardiac sarcoidosis (CS) is an increasingly recognized inflammatory cardiomyopathy that can present with ventricular arrhythmias and progressive heart failure (HF). Despite advances in various imaging modalities, notable regional differences persist in how ... Full text Link to item Cite

In-Hospital Initiation of SGLT2 Inhibitors in Patients with Acute Heart Failure: A Meta-analysis of Randomized Controlled Trials with Trial Sequential Analysis.

Journal article J Card Fail · April 29, 2026 BACKGROUND: Acute heart failure (AHF) remains a leading cause of hospitalization and mortality despite therapeutic advances. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown benefits in chronic HF, but their role when initiated during hospitali ... Full text Link to item Cite

Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Journal article JACC Heart Fail · April 2026 Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, which elevates the risks of hospitalization, disease progression, and death. Despite advances in treating each condition independently, many challenges remain in diagnosing and managin ... Full text Link to item Cite

Influenza vaccination in patients with heart failure: comprehensive review of evidence, challenges, and clinical implications.

Journal article Heart Fail Rev · March 14, 2026 Heart failure is a major global health burden, with high rates of hospitalization and mortality despite advances in medical therapy. Seasonal influenza is a well-established trigger for heart failure decompensation, acting through systemic inflammation, in ... Full text Link to item Cite

Purpose, Presence and How We Work.

Journal article J Card Fail · March 2026 Full text Link to item Cite

A multi-layered approach to elucidate mechanisms of physical function in response to rehabilitation in heart failure with preserved ejection fraction.

Journal article medRxiv · February 17, 2026 Heart failure with preserved ejection fraction (HFpEF) is an increasingly common cause of morbidity and mortality in older adults that is driven by cardiac and non-cardiac mechanisms. Physical rehabilitation improves frailty and functional capacity in HFpE ... Full text Link to item Cite

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Journal article Eur Heart J · February 11, 2026 BACKGROUND AND AIMS: In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently assess cardiovascular death. This study ... Full text Link to item Cite

Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.

Journal article ESC Heart Fail · February 3, 2026 INTRODUCTION: Iron deficiency (ID) is common among patients with heart failure (HF), and it is associated with poor functional outcomes, increased hospitalizations, and higher mortality. This meta-analysis evaluates the efficacy of intravenous ferric carbo ... Full text Link to item Cite

Heart Month and Her Heart Health Reimagined.

Journal article J Card Fail · February 2026 Full text Link to item Cite

Using Artificial Intelligence to Assess Treatment-Effect Heterogeneity in Pragmatic Cardiovascular Trials: Insights from TRANSFORM-HF.

Journal article medRxiv · January 19, 2026 BACKGROUND AND AIMS: Pragmatic clinical trials are designed to assess interventions in real-world settings, and their broad inclusion criteria and clinical variability create valuable opportunities for exploring heterogeneity of treatment effects. In this ... Full text Link to item Cite

Circulating Biomarkers as Predictors of Improvement in Physical Function in Hospitalized Older Adults With Geriatric Syndromes: Findings From the REHAB-HF Trial.

Journal article Circ Heart Fail · January 7, 2026 BACKGROUND: Biomarkers in heart failure (HF) provide mechanistic and prognostic insights, but their role in predicting treatment response is less understood. We evaluated whether multiple baseline biomarker profiles from the REHAB-HF trial (Rehabilitation ... Full text Link to item Cite

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials.

Journal article Future Cardiol · January 2026 BACKGROUND: Angiotensin receptor - neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This m ... Full text Link to item Cite

The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology.

Journal article J Card Fail · January 2026 Heart disease is the leading cause of death worldwide, with heart failure (HF) recognized as its most severe and debilitating manifestation. Though remarkable advancements have led to the establishment of life-saving and quality-of-life-enhancing medical a ... Full text Link to item Cite

Efficacy of cardiac myosin activators compared to placebo in patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.

Journal article Heart Lung · 2026 BACKGROUND: Cardiac myosin activators (CMAs) have been explored as a potential therapy to enhance cardiac contractility in patients with heart failure with reduced ejection fraction (HFrEF). However, their effect on clinical outcomes, including mortality, ... Full text Link to item Cite

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors.

Journal article Front Cardiovasc Med · 2026 Renin-angiotensin-aldosterone system (RAAS) blockade has been a mainstay of therapy in cardiovascular and kidney disease for nearly 30 years. Despite the development of multiple drug classes designed to intervene along the RAAS pathway, the residual risk f ... Full text Link to item Cite

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.

Journal article J Am Coll Cardiol · December 16, 2025 BACKGROUND: In the VICTOR (Vericiguat Global Study in Participants With Chronic Heart Failure) trial, in a contemporary ambulatory cohort with heart failure and reduced ejection fraction (HFrEF) and no recent hospitalization, the primary outcome of hospita ... Full text Link to item Cite

Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial.

Journal article J Card Fail · December 2025 BACKGROUND: The HEART-FID trial (Randomized Placebo-Controlled Trial of Ferric Carboxymaltose [FCM] as Treatment for Heart Failure with Iron Deficiency) is the largest trial to test intravenous iron (ferric carboxymaltose [FCM]) vs placebo in patients with ... Full text Link to item Cite

Changes in natriuretic peptide levels following patiromer-enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study.

Journal article Eur J Heart Fail · December 2025 AIMS: In the DIAMOND (Patiromer for the Management of Hyperkalaemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) trial, the potassium binder patiromer enabled optimization of renin-angiotensin-aldosterone system inhibitors (R ... Full text Link to item Cite

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.

Journal article Eur J Heart Fail · December 2025 AIMS: The efficacy and safety of vericiguat in patients with chronic heart failure with reduced ejection fraction (HFrEF) on contemporary heart failure (HF) therapies and without recent worsening was investigated in the VICTOR trial, yet some subgroups may ... Full text Link to item Cite

Navigating heart failure: a plain-language summary to empower people with heart failure.

Journal article Heart Fail Rev · December 2025 Heart failure is a chronic condition that can result from multiple causes and occurs when the heart cannot pump enough blood to meet the body's needs. Heart failure is often classified by ejection fraction (or 'heart squeeze'), into three categories: prese ... Full text Link to item Cite

Acute heart failure care - a consensus series of an international experts' group.

Journal article Eur J Heart Fail · December 2025 The care of patients hospitalized for acute heart failure (AHF) has been largely unchanged from the early 1960s until a few years ago, consisting mainly of oxygen and diuretics supplemented sometimes by other vasoactive drugs. These treatments, although ef ... Full text Link to item Cite

Early diagnosis and treatment of acute heart failure in prehospital and emergency settings. Part 1 of the International Expert Opinion Series on acute heart failure management.

Journal article Eur J Emerg Med · December 1, 2025 Acute heart failure (AHF) is diagnosed in about 0.5% of all patients seen by emergency medical systems (EMS) and represents about 1% of emergency department (ED) visits. Leg swelling and shortness of breath are the most frequent patient complaints. Despite ... Full text Link to item Cite

Early in-hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management.

Journal article ESC Heart Fail · December 2025 Acute heart failure (AHF) remains a major global health challenge, contributing significantly to morbidity, mortality and healthcare resource utilization. It is one of the leading causes of hospitalization, with persistently high readmission rates undersco ... Full text Link to item Cite

Special topics: heart failure-related cardiogenic shock, valvular heart disease and end-stage renal disease. Part 4 of the International Expert Opinion Series on Acute Heart Failure Management.

Journal article Heart Fail Rev · December 2025 Acute heart failure (AHF) remains a major global health challenge, contributing significantly to morbidity, mortality, and healthcare resource utilization. Among its clinical phenotypes, heart failure-related cardiogenic shock (HF-CS) represents a particul ... Full text Link to item Cite

Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID.

Journal article JACC Heart Fail · December 2025 BACKGROUND: Iron deficiency (ID) is common in patients with heart failure (HF), but optimal use of circulating iron indices as diagnostic criteria and for defining treatment targets remain uncertain. OBJECTIVES: This study sought how to determine how indiv ... Full text Link to item Cite

The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.

Journal article Am J Prev Cardiol · December 2025 Heart disease is the leading cause of death worldwide, with heart failure (HF) recognized as its most severe and debilitating manifestation. Though remarkable advancements have led to the establishment of life-saving and quality-of-life-enhancing medical a ... Full text Link to item Cite

GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Journal article Clin Cardiol · December 2025 This comprehensive meta-analysis reveals that GLP-1 and dual GLP-1/GIP receptor agonists are associated with reduced risk of composite cardiovascular endpoints and worsening heart failure events. However, no statistically significant differences were obser ... Full text Link to item Cite

AI-based approach for heart failure readmission prediction using SCG, ECG, and GSR signals.

Journal article Physiol Meas · November 4, 2025 Objective.Heart failure (HF) is considered a global pandemic because of increasing prevalence, high mortality rate, frequent hospitalization, and associated economic burden. This study explores a noninvasive method that may help in managing HF patients by ... Full text Link to item Cite

Optimal Diuretic Strategies for Chronic Heart Failure.

Journal article Med Clin North Am · November 2025 Loop diuretics are Class I recommended for managing congestion in chronic heart failure, though their effect on morbidity and mortality remains uncertain due to limited large-scale evidence. Current guidelines recommend using the lowest effective dose to m ... Full text Link to item Cite

Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute HF: The REHAB-HF Trial.

Journal article JACC Heart Fail · November 2025 BACKGROUND: A multidomain physical rehabilitation intervention (REHAB-HF [Rehabilitation Therapy in Older Acute Heart Failure Patients] intervention) has been associated with significant improvements in physical function and quality of life (QOL) among old ... Full text Link to item Cite

Cardiovascular Multimorbidity in Older Adults in the United States by Race and Sex.

Journal article JACC Adv · November 2025 BACKGROUND: It is essential to understand the prevalence of cardiovascular multimorbidity and to recognize disparities by race and sex to promote health equity. OBJECTIVES: The objectives of the study are to investigate disparities in the development and p ... Full text Open Access Link to item Cite

Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF.

Journal article Am Heart J · October 2025 BACKGROUND: Sub-analyses of key trials suggest a preferential benefit for specific heart failure with preserved ejection fraction (HFpEF) therapies in women. This work investigated treatment effects between women and men in the PARAGLIDE-HF (Prospective co ... Full text Link to item Cite

Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification.

Journal article ESC Heart Fail · October 2025 Clinical endpoint classification (CEC)-that is, evaluation of clinical events using pre-defined criteria-is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safe ... Full text Link to item Cite

Bringing it All Back Home.

Journal article J Card Fail · October 2025 Full text Link to item Cite

Optimizing Pre-to-Post Discharge Transition of Care in Patients Hospitalized for Heart Failure - Part 3 of the International Expert Opinion Series on Acute Heart Failure Management.

Journal article J Card Fail · September 28, 2025 Hospitalization for heart failure (HF) represents a pivotal event in the disease course, often signaling decompensation and an elevated risk of readmission, mortality, and functional decline. Despite advances in inpatient management, the transition from ho ... Full text Link to item Cite

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal article Lancet · September 27, 2025 BACKGROUND: Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to ... Full text Link to item Cite

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.

Journal article Lancet · September 27, 2025 BACKGROUND: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subse ... Full text Link to item Cite

The Value of Community in Heart Failure.

Journal article J Card Fail · September 2025 Full text Link to item Cite

Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.

Journal article J Card Fail · August 28, 2025 BACKGROUND: Randomized trials remain the standard for evaluating novel therapies. Primary endpoint(s) risk heterogeneity and may dilute treatment efficacy. The 5-step Stratified Testing and Amalgamation Routine (5-STAR) methodology helps to address these l ... Full text Link to item Cite

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.

Journal article Cardiovasc Diabetol · August 23, 2025 BACKGROUND: The objective of this study was to examine the degree to which conventional cardiovascular (CV) risk factor changes induced by once-weekly exenatide (EQW) might explain the placebo-controlled differences in CV outcomes observed in the Exenatide ... Full text Link to item Cite

Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.

Journal article Sci Rep · August 18, 2025 Ejection fraction (EF) is a key component of heart failure (HF) classification. However, the biologic basis of HF with mildly reduced EF (HFmrEF) as a distinct biologic entity distinct from HF with preserved EF (HFpEF) and reduced EF (HFrEF) has not been w ... Full text Link to item Cite

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.

Journal article Eur J Heart Fail · August 2025 AIMS: To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fract ... Full text Link to item Cite

Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency.

Journal article Nat Med · August 2025 Uncertainty remains about the effect of intravenous (i.v.) iron on outcomes for heart failure (HF) with iron deficiency. In the present study, we summarize the efficacy and safety of i.v. iron from six trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEAR ... Full text Link to item Cite

Independent and Joint Associations of Obesity and Hypertension on Incident Heart Failure: A Pooled Cohort Analysis.

Journal article Mayo Clin Proc · August 2025 OBJECTIVE: To assess the independent and combined associations of obesity and hypertension on incident heart failure (HF). METHODS: We studied participants of 3 epidemiologic cohorts: Atherosclerosis Risk in Communities (baseline visit 4, 1996-1998, to fol ... Full text Link to item Cite

August: Time to Pause-with a Purpose.

Journal article J Card Fail · August 2025 Full text Link to item Cite

Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement.

Journal article J Clin Med · July 9, 2025 Background/Objectives: The development of hypophosphatemia has been associated with intravenous iron products, with the rate of hypophosphatemia found to be higher with ferric carboxymaltose. This consensus statement provides clinical guidance on the risk ... Full text Link to item Cite

Type 2 Diabetes Mellitus-Related Mortality in the United States, 1999 to 2023.

Journal article JACC Adv · July 2025 BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) has increased in the United States, contributing significantly to morbidity and mortality. OBJECTIVES: This study analyzes trends in T2DM-related mortality focusing on demographic and regional d ... Full text Link to item Cite

Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials.

Journal article Res Pract Thromb Haemost · July 2025 BACKGROUND: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality globally. Although direct oral anticoagulants (DOACs) have improved extended VTE treatment, the optimal dose for balancing efficacy and safety remains uncle ... Full text Link to item Cite

Worldwide prevalence of chagas cardiomyopathy-an analysis from the global burden of disease dataset.

Journal article Infection · June 2025 PURPOSE: The worldwide prevalence of Chagas Cardiomyopathy (CCM) as well as the trends in the prevalence of CCM over time have not been well characterized. METHODS: An analysis of the Global Burden of Disease (GBD) data from 1990 to 2019 was conducted to a ... Full text Link to item Cite

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.

Journal article Eur J Heart Fail · May 2025 AIMS: Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced hypophosphataemia ... Full text Link to item Cite

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis.

Journal article Eur J Heart Fail · May 2025 AIMS: This post hoc analysis aimed to assess the efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist finerenone by baseline diuretic use in FIDELITY, a pre-specified pooled analysis of the phase III trials FIDELIO-DKD and FIGARO- ... Full text Link to item Cite

Towards a person-centered after-visit summary to facilitate improved heart failure care (HF-AVS): A scoping review and call to action.

Journal article Am Heart J · May 2025 Person-centered care (PCC) has been advanced as an optimal model for chronic heart failure management in multiple guidelines. However, fulfilling the ideal of this model requires overcoming healthcare fragmentation via effective provider-to-patient communi ... Full text Link to item Cite

Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints.

Journal article Stat Med · May 2025 Win measures, such as win ratio, win odds, net benefit, and desirability of outcome ranking (DOOR), have become popular approaches for the analysis of hierarchical endpoints in clinical studies. Sample size and power calculations with win measures based on ... Full text Link to item Cite

Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.

Journal article ESC Heart Fail · April 2025 AIMS: The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment ef ... Full text Link to item Cite

Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis.

Journal article Eur J Heart Fail · April 2025 AIMS: Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF and low BP is currently unknown. The aim of this study w ... Full text Link to item Cite

Epicardial Fat in Heart Failure and Preserved Ejection Fraction: Novel Insights and Future Perspectives.

Journal article Curr Heart Fail Rep · March 19, 2025 PURPOSE OF REVIEW: Cardiovascular effects of obesity may be driven, in part, by the distribution of fat. More recently, epicardial adipose tissue (EAT) has gained recognition as an adverse visceral fat impacting cardiac dysfunction in heart failure with pr ... Full text Open Access Link to item Cite

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial.

Journal article J Am Heart Assoc · March 4, 2025 BACKGROUND: Efficacy and tolerability of sacubitril/valsartan (Sac/Val) is not well characterized in heart failure (HF) with ejection fraction >40% initiated in-hospital. Thus, this prespecified PARAGLIDE-HF (Prospective Comparison of ARNI With ARB Given F ... Full text Link to item Cite

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.

Journal article Nat Commun · March 3, 2025 Genomics can provide insight into the etiology of type 2 diabetes and its comorbidities, but assigning functionality to non-coding variants remains challenging. Polygenic scores, which aggregate variant effects, can uncover mechanisms when paired with mole ... Full text Link to item Cite

Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study.

Journal article Eur J Heart Fail · March 2025 AIMS: The extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heart failure (HF) incidence and subtypes, remains unclear. We assessed the association of MetS with incident HF (including ejection fraction subtyp ... Full text Link to item Cite

Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.

Journal article Eur J Heart Fail · March 2025 AIMS: Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events (MACE) and cardiovascular mortality in people with type 2 diabetes (T2D). However, previous studies suggest the effects on heart failure outcomes vary according to l ... Full text Link to item Cite

Association of Double-Blind Reviews With Increases in Women as First Authors: An Initial Report From the Journal of Cardiac Failure.

Journal article J Card Fail · March 2025 INTRODUCTION: Women continue to remain under-represented in academic publishing in the field of cardiology. Some evidence suggests that double-blind peer reviews may mitigate the impact of gender bias. In July 2021, the Journal of Cardiac Failure implement ... Full text Link to item Cite

Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF.

Journal article JACC Basic Transl Sci · March 2025 Growing evidence supports therapeutic ketosis in heart failure with reduced ejection fraction, though uncertainty exists regarding use with SGLT2i and dose-dependent effects. In a phase I trial of 2 ketone ester (KE) doses in 20 heart failure with reduced ... Full text Link to item Cite

Diabetes, Subclinical Myocardial Injury or Stress, and Risk of Heart Failure Subtypes: The Jackson Heart Study.

Journal article Diabetes Care · March 1, 2025 OBJECTIVE: To assess the extent to which the concomitant presence of subclinical myocardial injury or stress and diabetes affects the risk of heart failure (HF) subtypes. RESEARCH DESIGN AND METHODS: The Jackson Heart Study included Black adults, categoriz ... Full text Link to item Cite

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.

Journal article Eur J Heart Fail · February 2025 AIMS: The TRANSFORM-HF trial found no difference in clinical outcomes between torsemide versus furosemide after hospitalization for heart failure. This analysis aimed to assess the impact of diuretic dosing on the primary and secondary clinical outcomes. M ... Full text Link to item Cite

Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.

Journal article Eur J Heart Fail · February 2025 AIMS: In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in ... Full text Link to item Cite

Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF.

Journal article Am Heart J · February 2025 BACKGROUND: The win ratio (WR) is an emerging alternative for reporting composite outcomes, prioritizing clinically significant events such as mortality while incorporating surrogate measures. However, its benefits should be weighed against limitations, pa ... Full text Link to item Cite

Mechanistic Differences between Torsemide and Furosemide.

Journal article J Am Soc Nephrol · January 1, 2025 KEY POINTS: Oral torsemide was not superior to furosemide in measures of renal tubular delivery or duration of action. A dose equivalence of approximately 40 mg oral furosemide:10 mg oral torsemide resulted in similar natriuresis. The two-fold higher doses ... Full text Link to item Cite

Effects of fortified eggs and time-restricted eating on cardiometabolic health: The prosperity trial.

Journal article Am Heart J · January 2025 BACKGROUND: Given the increasing interest in dietary interventions to improve cardiovascular health, this trial assessed the impact of fortified eggs (FE) versus nonegg supplemented diet and time-restricted eating (TRE) versus usual care diet on cardiovasc ... Full text Link to item Cite

Diuretic Potentiation Strategies in Acute Heart Failure.

Journal article JACC Heart Fail · January 2025 Several trials have evaluated diuretic-based strategies to improve symptoms and outcomes in patients with acute heart failure (AHF). The authors sought to summarize the effect of different combination strategies on symptoms, physical signs, physiological v ... Full text Link to item Cite

The JCF 2024 Year-In-Review.

Journal article J Card Fail · January 2025 Full text Link to item Cite

EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure.

Journal article Cardiorenal Med · 2025 BACKGROUND: Hyperkalemia, generally defined as serum potassium levels greater than 5.0 mEq/L, poses significant clinical risks, including cardiac toxicity and muscle weakness. Its prevalence and severity increase in patients with chronic kidney disease (CK ... Full text Link to item Cite

Integrating cardiovascular implementation science research within healthcare systems.

Journal article Prog Cardiovasc Dis · 2025 Only 1 in 5 evidence-based interventions make it to routine clinical practice and the evidence generated from clinical research may take 17 years to be implemented. This represents a lost opportunity to improve clinical care in healthcare systems. Implemen ... Full text Link to item Cite

Heart rate variability in patients with cardiovascular diseases.

Journal article Prog Cardiovasc Dis · 2025 Heart rate variability (HRV) has been reported to predict overall mortality and the risk of cardiovascular disease events in patients, including those with heart failure. However, inconsistent methods of recording and analyzing HRV parameters, along with a ... Full text Link to item Cite

Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study.

Journal article Sci Rep · December 30, 2024 BAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF) ... Full text Link to item Cite

Cigarette Smoking, Smoking Cessation, and Heart Failure Subtypes: Insights From the Jackson Heart Study.

Journal article J Am Heart Assoc · December 3, 2024 BACKGROUND: Cigarette smoking has been associated with incident heart failure (HF). However, the association between cigarette smoking and smoking cessation with HF subtypes has not been well elucidated, particularly among Black people. METHODS AND RESULTS ... Full text Link to item Cite

Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial.

Journal article J Card Fail · December 2024 BACKGROUND: In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsar ... Full text Link to item Cite

Management of Iron Deficiency in Heart Failure: Practical Considerations and Implementation of Evidence-Based Iron Supplementation.

Journal article JACC Heart Fail · December 2024 Iron deficiency (ID) is present in approximately 50% of patients with heart failure (HF) and even higher prevalence rate up to 80% in post-acute HF setting. The current guidelines for HF recommend intravenous (IV) iron replacement in HF with reduced or mil ... Full text Link to item Cite

Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role.

Journal article JACC Heart Fail · December 2024 The pathophysiology of heart failure (HF) is related to the overactivation of the mineralocorticoid receptor, leading to fluid retention and adverse myocardial remodeling. Although mineralocorticoid receptor antagonists (MRAs) are recommended for the treat ... Full text Link to item Cite

Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis.

Journal article JACC Heart Fail · December 2024 BACKGROUND: For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium bin ... Full text Link to item Cite

Abdominal Compared With Coronary Artery Calcification and Incident Cardiovascular Events and Mortality in Black Adults.

Journal article Circ Cardiovasc Imaging · December 2024 BACKGROUND: Black adults show heightened cardiovascular risk compared with other groups despite comparable or lower coronary artery calcium (CAC) scores, indicating potential cardiovascular risk underestimation by CAC. Abdominal aortic calcification (AAC), ... Full text Link to item Cite

A Time for Reflection and Renewal.

Journal article J Card Fail · December 2024 Full text Link to item Cite

Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction.

Journal article Heart Fail Rev · November 2024 The concept of quadruple therapy as a "one-size-fit-all" approach is effective among all eligible patients with heart failure with reduced ejection fraction, with consistent and significant clinical benefits including reduced mortality across various subgr ... Full text Link to item Cite

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Journal article Circ Heart Fail · November 2024 BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar ef ... Full text Link to item Cite

Spotlight on Devices in Heart Failure.

Journal article J Card Fail · November 2024 Full text Link to item Cite

Correction.

Journal article JACC Heart Fail · November 2024 Full text Link to item Cite

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.

Journal article Alzheimers Res Ther · October 2, 2024 BACKGROUND: Glucagon-like peptide-1 receptor agonists are a viable option for the prevention of Alzheimer's disease (AD) but the mechanisms of this potential disease modifying action are unclear. We investigated the effects of once-weekly exenatide (EQW) o ... Full text Link to item Cite

Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction.

Journal article ESC Heart Fail · October 2024 AIMS: The objective of this study was to examine associations between elevated depressive symptoms and increased risk of adverse clinical events patients with heart failure and reduced ejection fraction (HFrEF), as well as the potential contribution of hea ... Full text Link to item Cite

Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction.

Journal article ESC Heart Fail · October 2024 AIMS: Clinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the generalizability of ... Full text Link to item Cite

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial.

Journal article JAMA Cardiol · October 1, 2024 IMPORTANCE: Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors' knowledge, no prior randomized clinical ... Full text Link to item Cite

Atrial Fibrillation Status and Physical Rehabilitation in Older Patients With Acute Decompensated Heart Failure: An Analysis From the REHAB-HF Trial.

Journal article J Am Heart Assoc · October 2024 BACKGROUND: The REHAB-HF (Rehabilitation Therapy in Older Acute Heart Failure Patients) trial demonstrated that a transitional, tailored, progressive rehabilitation intervention improved physical function, 6-minute walk distance, frailty, quality-of-life, ... Full text Link to item Cite

Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.

Journal article J Am Coll Cardiol · October 1, 2024 BACKGROUND: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: This study sought to assess charac ... Full text Link to item Cite

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE.

Journal article Eur J Heart Fail · September 2024 AIMS: Patients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the efficacy and safe ... Full text Link to item Cite

Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.

Journal article Heart Fail Rev · September 2024 Quadruple therapy is effective for patients with heart failure with reduced ejection fraction, providing significant clinical benefits, including reduced mortality. Clinicians are now in an era focused on how to initiate and titrate quadrable therapy in th ... Full text Link to item Cite

Carbon emissions and air pollution savings among telehealth visits for cardiology appointments.

Journal article Am Heart J Plus · September 2024 BACKGROUND: Climate change has been associated with adverse cardiovascular health, prompting interest in climate mitigation strategies while improving access for cardiovascular patients. We estimated greenhouse gas and air pollution savings from telehealth ... Full text Link to item Cite

Impact as a Metric: Always in Motion.

Journal article J Card Fail · September 2024 Full text Link to item Cite

Neighborhood Socioeconomic Disadvantage and 30-Day Outcomes for Common Cardiovascular Conditions.

Journal article J Am Heart Assoc · August 20, 2024 BACKGROUND: Understanding the relationship between neighborhood environment and cardiovascular outcomes is important to achieve health equity and implement effective quality strategies. We conducted a population-based cohort study to determine the associat ... Full text Link to item Cite

Severe obesity among patients with left ventricular assist devices.

Journal article Am Heart J · August 2024 BACKGROUND: Patients with obesity and advanced heart failure requiring left ventricular assist device (LVAD) support are more likely to experience LVAD complications and may be disproportionately Black and/or female when compared to patients without obesit ... Full text Link to item Cite

Peripheral artery disease, chronic kidney disease, and recurrent admissions for acute decompensated heart failure: The ARIC study.

Journal article Atherosclerosis · August 2024 BACKGROUND AND AIMS: Peripheral artery disease (PAD) has not only been associated with recurrent hospitalization for acute decompensated heart failure (ADHF) but is also associated with chronic kidney disease (CKD), a known risk factor for worse heart fail ... Full text Link to item Cite

Trajectory of C-Reactive Protein and Incident Heart Failure in Black Adults: The Jackson Heart Study.

Journal article Circ Heart Fail · August 2024 BACKGROUND: Increased hsCRP (high-sensitivity C-reactive protein), a marker of inflammation, is associated with incident cardiovascular events. We aim to determine whether the baseline or trajectory of hsCRP levels over time predicts incident heart failure ... Full text Link to item Cite

JCF Purple for Patients.

Journal article J Card Fail · August 2024 Full text Link to item Cite

Identification of three mechanistic pathways for iron-deficient heart failure.

Journal article Eur Heart J · July 9, 2024 Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, ... Full text Link to item Cite

Redefining Iron Deficiency in Patients With Chronic Heart Failure.

Journal article Circulation · July 9, 2024 A serum ferritin level <15 to 20 μg/L historically identified patients who had absent bone marrow iron stores, but serum ferritin levels are distorted by the systemic inflammatory states seen in patients with chronic kidney disease or heart failure. As a r ... Full text Link to item Cite

On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.

Journal article Eur J Heart Fail · July 2024 AIM: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought ... Full text Link to item Cite

Cardiovascular Burden of the V142I Transthyretin Variant.

Journal article JAMA · June 4, 2024 IMPORTANCE: Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin (TTR) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant ... Full text Link to item Cite

Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure.

Journal article Eur J Heart Fail · June 2024 According to current guidelines, iron deficiency is defined by a serum ferritin level <100 ng/ml or a transferrin saturation (TSAT) <20% if the serum ferritin level is 100-299 μg/L. These criteria were developed to encourage the use of intravenous iron as ... Full text Link to item Cite

Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF.

Journal article JACC Adv · June 2024 BACKGROUND: Decompensated heart failure (HF) can be categorized as de novo or worsening of chronic HF. In PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF), among patients with an ejection fraction  ... Full text Link to item Cite

Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.

Journal article J Am Coll Cardiol · May 7, 2024 BACKGROUND: Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in heart failure (HF) with mildly reduced and preserved ejection fraction. ... Full text Link to item Cite

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.

Journal article JACC Heart Fail · May 2024 BACKGROUND: In VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), vericiguat compared with placebo reduced cardiovascular death or heart failure (HF) hospitalization in patients with HF with reduced ejection f ... Full text Link to item Cite

Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.

Journal article Am Heart J · May 2024 AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ... Full text Link to item Cite

Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.

Journal article Eur J Heart Fail · May 2024 AIM: Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all-cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney ... Full text Link to item Cite

Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.

Journal article J Am Coll Cardiol · April 23, 2024 Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse ... Full text Link to item Cite

Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF.

Journal article JACC Heart Fail · April 2024 BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy is recommended to reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is common among patients with HFrEF and is associated with increased mor ... Full text Link to item Cite

Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.

Journal article Eur J Heart Fail · April 2024 Sodium and fluid restriction has traditionally been advocated in patients with heart failure (HF) due to their sodium and water avid state. However, most evidence regarding the altered sodium handling, fluid homeostasis and congestion-related signs and sym ... Full text Link to item Cite

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.

Journal article J Am Coll Cardiol · March 26, 2024 BACKGROUND: The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described. OBJECTIVES: Data from randomized trials of sacubitril/valsar ... Full text Link to item Cite

Patient Risk-Benefit Preferences for Transcatheter Versus Surgical Mitral Valve Repair.

Journal article J Am Heart Assoc · March 19, 2024 BACKGROUND: Transcatheter edge-to-edge repair (TEER) of mitral regurgitation is less invasive than surgery but has greater 5-year mortality and reintervention risks, and leads to smaller improvements in physical functioning. The study objective was to quan ... Full text Link to item Cite

Abstract P304: Sex Differences for the Progression of Cardiovascular Multimorbidity in Older Adults in the United States

Journal article Circulation · March 19, 2024 Introduction: Understanding the progression of cardiovascular multimorbidity and recognizing differences are needed to develop effective strategies to improve health outcomes. There is a knowledge gap ... Full text Cite

Abstract 48: Racial and Ethnic Disparities in Cardiovascular Multimorbidity Progression Among Older United States Adults

Journal article Circulation · March 19, 2024 Introduction: There is a knowledge gap in the potential unequal burden and progression of cardiovascular multimorbidity. Understanding the progression of cardiovascular multimorbidity and recognizing ... Full text Cite

3D Printing for Left Ventricular Assist Device Exchange: Insights From Real-World Experience.

Journal article JACC Case Rep · March 6, 2024 Left ventricular assist devices (LVADs) are used in end-stage heart failure. Inadequate positioning of the inflow cannula may necessitate replacement of the LVAD. We present the successful use of a three-dimensional printed model used to optimize surgical ... Full text Open Access Link to item Cite

Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.

Journal article Cardiol Rev · March 2024 Various pharmacotherapies exist for heart failure with preserved ejection fraction (HFpEF), but with unclear comparative efficacy. We searched EMBASE, Medline, and Cochrane Library from inception through August 2021 for all randomized clinical trials in HF ... Full text Link to item Cite

Costs of care and financial hardship among patients with heart failure.

Journal article Am Heart J · March 2024 With the implementation of new therapies, more patients are living with heart failure (HF) as a chronic condition. Alongside these advances, out-of-pocket (OOP) medical costs have increased, and patients experience significant financial burden. Despite inc ... Full text Link to item Cite

A Phenomapping Tool and Clinical Score to Identify Low Diuretic Efficiency in Acute Decompensated Heart Failure.

Journal article JACC Heart Fail · March 2024 BACKGROUND: Individuals with acute decompensated heart failure (ADHF) have a varying response to diuretic therapy. Strategies for the early identification of low diuretic efficiency to inform decongestion therapies are lacking. OBJECTIVES: The authors soug ... Full text Link to item Cite

Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.

Journal article Circ Heart Fail · March 2024 BACKGROUND: The TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) found no significant difference in all-cause mortality or hospitalization among patients randomized to a strategy of torsemide versus furosemide follo ... Full text Link to item Cite

Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.

Journal article Eur J Heart Fail · March 2024 AIMS: In VICTORIA, vericiguat compared with placebo reduced the risk of cardiovascular death (CVD) and heart failure hospitalization (HFH) in patients enrolled after a worsening heart failure (WHF) event. We examined clinical outcomes and efficacy of veric ... Full text Link to item Cite

The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference.

Journal article Journal of cardiac failure · February 2024 There is waning interest among cardiology trainees in pursuing an Advanced Heart Failure/Transplant Cardiology (AHFTC) fellowship as evidenced by fewer applicants in the National Resident Matching Program match to this specialty. This trend has generated c ... Full text Cite

Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.

Journal article JAMA Cardiol · February 1, 2024 IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). OBJECTIVES: To compare clinical characteristics and treatment outcomes of tors ... Full text Link to item Cite

Improving Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: A Review of Implementation Strategies.

Journal article J Card Fail · February 2024 Despite recent advances in the use of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), achievement of target GDMT use and up-titration to goal dosages continue to be modest. In recent years, ... Full text Open Access Link to item Cite

Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial.

Journal article Circ Heart Fail · February 2024 BACKGROUND: Clinical trials in heart failure (HF) traditionally use time-to-event analyses focusing on death and hospitalization for HF. These time-to-first event analyses may have more limited abilities to assess the probability of benefiting from a thera ... Full text Link to item Cite

The Heart as a Reminder for Oneness.

Journal article J Card Fail · February 2024 Full text Link to item Cite

Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper.

Journal article JACC Heart Fail · January 2024 Acute decompensated heart failure (ADHF) is one of the most common reasons for hospitalizations or urgent care and is associated with poor outcomes. Therapies shown to improve outcomes are limited, however, and innovation in pharmacologic and device-based ... Full text Link to item Cite

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.

Journal article Eur J Heart Fail · January 2024 Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A. Borger (Germany), Sergio Bucche ... Full text Link to item Cite

Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.

Journal article Am J Nephrol · 2024 INTRODUCTION: Renin-angiotensin-aldosterone system inhibitor (RAASi; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); howe ... Full text Link to item Cite

Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.

Journal article Eur Heart J · December 21, 2023 BACKGROUND AND AIMS: Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinica ... Full text Link to item Cite

Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial.

Journal article Am Heart J · December 2023 BACKGROUND: Prior clinical trials have investigated intravenous iron in patients with heart failure (HF) and iron deficiency, but the safety and efficacy of this therapy remains unclear. METHODS: We report the baseline demographics and clinical characteris ... Full text Link to item Cite

JCF and HFSA Collaborations into 2024.

Journal article J Card Fail · December 2023 Full text Link to item Cite

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.

Journal article Cardiovasc Diabetol · November 16, 2023 BACKGROUND: Heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) are common and interrelated conditions, each with a significant burden of disease. HF and kidney disease progress through pathophysiologic pathways that culmi ... Full text Link to item Cite

Relationship of Race With Functional and Clinical Outcomes With the REHAB-HF Multidomain Physical Rehabilitation Intervention for Older Patients With Acute Heart Failure.

Journal article J Am Heart Assoc · November 7, 2023 Background The REHAB-HF (Rehabilitation Therapy in Older Acute Heart Failure Patients) randomized trial demonstrated that a 3-month transitional, tailored, progressive, multidomain physical rehabilitation intervention improves physical function, frailty, d ... Full text Link to item Cite

Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction.

Journal article Circ Heart Fail · November 2023 Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations. HFpEF is associated with significant morbidity and mortality that may benefit from incorporation ... Full text Link to item Cite

Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors.

Journal article Am J Cardiol · October 1, 2023 Sacubitril/valsartan improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with angiotensin-converting enzyme inhibitors (ACEis). However, data on postdischarge outcomes in renin-angiotensin system inhibitor (RASi ... Full text Link to item Cite

Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.

Journal article Eur J Heart Fail · October 2023 AIMS: In patients hospitalized for acute heart failure (AHF) empagliflozin produced greater clinical benefit than placebo. Many patients with AHF are treated with mineralocorticoid receptor antagonists (MRAs). The interplay between empagliflozin and MRAs i ... Full text Link to item Cite

Patient mortality following new-onset heart failure stratified by cancer type and status.

Journal article Eur J Heart Fail · October 2023 AIM: Expected 1-year survival is essential to risk stratification of patients with heart failure (HF); however, little is known about the 1-year prognosis of patients with HF and cancer. Thus, the objective was to investigate the 1-year prognosis following ... Full text Link to item Cite

Ferric Carboxymaltose in Heart Failure with Iron Deficiency.

Journal article N Engl J Med · September 14, 2023 BACKGROUND: Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effects of ferric carboxymaltose on clinical even ... Full text Link to item Cite

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.

Journal article JCI Insight · September 8, 2023 Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial dysfunction pr ... Full text Link to item Cite

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.

Journal article Eur Heart J · August 14, 2023 AIMS: The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but w ... Full text Link to item Cite

Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.

Journal article J Am Coll Cardiol · August 8, 2023 Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline ... Full text Link to item Cite

High-Intensity Interval Training Versus Moderate Continuous Training in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-analysis.

Journal article Curr Probl Cardiol · August 2023 High-intensity interval training (HIIT) is a novel training approach that improves cardiopulmonary fitness and functional capacity in numerous chronic conditions, however its impact in patients with heart failure (HF) with preserved ejection fraction (HFpE ... Full text Link to item Cite

Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.

Journal article Circulation · July 11, 2023 BACKGROUND: Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRAN ... Full text Link to item Cite

Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.

Journal article J Am Coll Cardiol · July 4, 2023 BACKGROUND: U.S. guidelines recommend consideration of sacubitril/valsartan in chronic heart failure (HF) and mildly reduced or preserved ejection fraction (EF). Whether initiation is safe and effective in EF >40% after a worsening heart failure (WHF) even ... Full text Link to item Cite

Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America.

Journal article J Card Fail · July 2023 Iron deficiency is present in approximately 50% of patients with symptomatic heart failure and is independently associated with worse functional capacity, lower quality of, life and increased mortality. The purpose of this document is to summarize current ... Full text Link to item Cite

Hand Grip Strength Predicts Mortality and Quality of Life in Heart Failure: Insights From the Singapore Cohort of Patients With Advanced Heart Failure.

Journal article J Card Fail · June 2023 BACKGROUND: Frailty is prevalent among patients with heart failure (HF) and is associated with increased mortality rates and worse patient-centered outcomes. Hand grip strength (GS) has been proposed as a single-item marker of frailty and a potential scree ... Full text Link to item Cite

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal article Diabetes Obes Metab · June 2023 AIM: To examine sex differences in the characteristics and outcomes in participants with type 2 diabetes (T2D), with or without cardiovascular disease (CVD), randomized to once-weekly exenatide (EQW) or placebo in the Exenatide Study of Cardiovascular Even ... Full text Link to item Cite

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.

Journal article J Card Fail · June 2023 BACKGROUND: The PARAGON-HF trial studied the effect of sacubitril/valsartan (Sac/Val) compared with valsartan (Val) on clinical outcomes in patients with chronic heart failure with preserved ejection fraction (HFpEF) or mildly reduced EF (HFmrEF). Further ... Full text Link to item Cite

Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials.

Journal article Eur Heart J · June 1, 2023 Conventional randomized controlled trials (RCTs) can be expensive, time intensive, and complex to conduct. Trial recruitment, participation, and data collection can burden participants and research personnel. In the past two decades, there have been rapid ... Full text Link to item Cite

Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.

Journal article Eur J Heart Fail · May 2023 Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementar ... Full text Link to item Cite

Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.

Journal article J Card Fail · May 2023 Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementar ... Full text Link to item Cite

Using Data to Facilitate Peer Reviewer Engagement - A JCF Update

Journal article Journal of Cardiac Failure · May 1, 2023 Full text Cite

Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

Journal article Circ Heart Fail · May 2023 BACKGROUND: Heart failure (HF) guidelines recommend assessment of left ventricular ejection fraction (LVEF) to classify patients and guide therapy implementation. However, LVEF alone may be insufficient to adequately characterize patients with HF, especial ... Full text Link to item Cite

Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials.

Journal article J Card Fail · April 2023 BACKGROUND: Randomized controlled trials (RCTs) may report outcomes different from those prespecified on trial-registration websites, protocols and statistical analysis plans (SAPs). This study sought to investigate the prevalence and characteristics of he ... Full text Link to item Cite

Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis.

Journal article ESC Heart Fail · April 2023 AIMS: There is considerable variability in the effect of intravenous iron on hard cardiovascular (CV)-related outcomes in patients with heart failure (HF) in randomized controlled trials (RCTs). We use a meta-analytic approach to analyse data from existing ... Full text Link to item Cite

Vericiguat for the treatment of heart failure with reduced ejection fraction.

Journal article Expert Rev Cardiovasc Ther · April 2023 INTRODUCTION: Despite significant therapeutic advancements in heart failure with reduced ejection fraction (HFrEF), the residual risk of all-cause mortality and hospitalizations remains high among patients with HFrEF. Vericiguat is a novel oral soluble gua ... Full text Link to item Cite

Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study.

Journal article J Am Heart Assoc · March 21, 2023 Background Diabetes and hypertension have been associated with adverse left ventricular (LV) remodeling. While they often occur concurrently, their individual effects are understudied. We aimed to assess the independent effects of diabetes and hypertension ... Full text Link to item Cite

Continuous Monitoring of Heart Rate Variability and Clinical Outcomes in Patients with Implantable Cardioverter Defibrillators.

Journal article Curr Probl Cardiol · March 2023 While heart rate variability (HRV) is an established marker of cardiovascular health, the extent to which continuously measured HRV changes over time and the relationship between these changes and clinical outcomes are less clear. We performed a health sys ... Full text Link to item Cite

Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events.

Journal article J Card Fail · March 2023 Vericiguat is a soluble guanylate cyclase stimulator approved by multiple global regulatory bodies and recommended in recently updated clinical practice guidelines to reduce morbidity and mortality in patients with worsening chronic heart failure (HF) with ... Full text Link to item Cite

Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions.

Journal article Cardiovasc Res · February 3, 2023 Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity with complex pathophysiology and manifestations. Phenomapping is the process of applying statistical learning techniques to patient data to identify distinct subgroups based o ... Full text Link to item Cite

Mechanisms of current therapeutic strategies for heart failure: more questions than answers?

Journal article Cardiovasc Res · February 3, 2023 Heart failure (HF) is a complex, multifactorial and heterogeneous syndrome with substantial mortality and morbidity. Over the last few decades, numerous attempts have been made to develop targeted therapies that may attenuate the known pathophysiological p ... Full text Link to item Cite

Do PRO Measures Function the Same Way for all Individuals With Heart Failure?

Journal article J Card Fail · February 2023 Women diagnosed with heart failure report worse quality of life than men on patient-reported outcome (PRO) measures. An inherent assumption of PRO measures in heart failure is that women and men interpret questions about quality of life the same way. If th ... Full text Link to item Cite

Vitamin D Levels in Black Americans and the Association With Left Ventricular Remodeling and Incident Heart Failure With Preserved Ejectin Fraction: The Jackson Heart Study.

Journal article J Card Fail · February 2023 BACKGROUND: In observational studies, a lower serum vitamin D3 concentration has been associated with an increased risk of cardiovascular disease. However, the associations between serum vitamin D3 levels and left ventricular (LV) structure and heart failu ... Full text Link to item Cite

In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial.

Journal article Circ Heart Fail · February 2023 BACKGROUND: Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) improves clinical outcomes and quality of life. Optimizing GDMT in the hospital is associated with greater long-term use in HFrEF. This study aim ... Full text Link to item Cite

Physical activity and relationship to physical function, quality of life, and cognitive function in older patients with acute decompensated heart failure.

Journal article Am Heart J · February 2023 BACKGROUND: Volitional physical activity level is predictive of a variety of health outcomes, but has not been examined in patients recently hospitalized for acute decompensated HF (ADHF). METHODS: Ten to 14 days after index hospitalization for ADHF, 93 pa ... Full text Link to item Cite

Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.

Journal article JAMA Cardiol · February 1, 2023 IMPORTANCE: Frailty is common among older patients with acute decompensated heart failure (ADHF) and is associated with worse quality of life (QOL) and a higher risk of clinical events. Frailty can also limit recovery and response to interventions. In the ... Full text Link to item Cite

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.

Journal article JAMA · January 17, 2023 IMPORTANCE: Although furosemide is the most commonly used loop diuretic in patients with heart failure, some studies suggest a potential benefit for torsemide. OBJECTIVE: To determine whether torsemide results in decreased mortality compared with furosemid ... Full text Link to item Cite

Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults.

Journal article J Card Fail · January 2023 BACKGROUND: Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is associated with heart failure (HF) risk. The association of longitudinal changes in hs-cTnI with risk of incident HF, HF with reduced and preserved ejection fraction (HFrEF an ... Full text Link to item Cite

Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.

Journal article Circ Heart Fail · January 2023 BACKGROUND: Alignment between clinician-reported New York Heart Association (NYHA) class compared and patient-reported outcomes among patients hospitalized for heart failure is unclear. METHODS: ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritid ... Full text Link to item Cite

Anabolic androgenic steroids and cardiomyopathy: an update.

Journal article Front Cardiovasc Med · 2023 Anabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an ... Full text Link to item Cite

Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction.

Journal article J Card Fail · December 2022 BACKGROUND: Differences between patients hospitalized for heart failure with reduced ejection fraction (HFrEF) vs HF with preserved EF (HFpEF) are not well-characterized, particularly as pertains to in-hospital decongestion and longitudinal patient-reporte ... Full text Link to item Cite

Severity of functional impairments by race and sex in older patients hospitalized with acute decompensated heart failure.

Journal article J Am Geriatr Soc · December 2022 BACKGROUND: Older patients hospitalized with acute decompensated heart failure (ADHF) have marked functional impairments, which may contribute to their delayed and incomplete recovery and persistently poor outcomes. However, whether impairment severity dif ... Full text Link to item Cite

Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF.

Journal article Am Heart J · December 2022 BACKGROUND: Heart Failure with Preserved Ejection Fraction (HFpEF) is a heterogenous disease with few therapies proven to provide clinical benefit. Machine learning can characterize distinct phenotypes and compare outcomes among patients with HFpEF who are ... Full text Link to item Cite

Evaluation and Treatment of Central Sleep Apnea in Patients with Heart Failure.

Journal article Curr Probl Cardiol · December 2022 Sleep-disordered breathing (SDB) is a common comorbidity in patients with heart failure (HF). Prevalence of the most common subtypes of SDB, central sleep apnea (CSA) and obstructive sleep apnea (OSA), is increasing, which is concerning due to the associat ... Full text Link to item Cite

Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF.

Journal article JACC Heart Fail · December 2022 BACKGROUND: In the REHAB-HF (Rehabilitation Therapy in Older Acute Heart Failure Patients) trial, a novel, early, transitional, multidomain rehabilitation intervention improved physical function, frailty, quality of life (QOL), and depression in older pati ... Full text Link to item Cite

Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial.

Journal article Circ Heart Fail · December 2022 BACKGROUND: As patients with heart failure experience worsening of their condition, including acute decompensated heart failure, quality of life deteriorates. However, the trajectory of quality of life changes and their determinants in the context of the R ... Full text Link to item Cite

Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel.

Journal article JACC Heart Fail · December 2022 The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and the Academic Research Consortium (ARC) composed of patients, academic investigators from the United States and Europe, the U.S. Food and Drug ... Full text Link to item Cite

She Was One of Us. Remembering Dr. Lauren Gilstrap

Journal article Journal of Cardiac Failure · December 2022 Full text Cite

Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events.

Journal article Sci Rep · November 22, 2022 There is increasing evidence that HFpEF is a heterogeneous clinical entity and distinct molecular pathways may contribute to pathophysiology. Leveraging unbiased proteomics to identify novel biomarkers, this study seeks to understand the underlying molecul ... Full text Link to item Cite

The need for increased pragmatism in cardiovascular clinical trials.

Journal article Nat Rev Cardiol · November 2022 The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety ... Full text Link to item Cite

A Randomized Controlled Trial of Mobile Health Intervention in Patients With Heart Failure and Diabetes.

Journal article J Card Fail · November 2022 BACKGROUND: Mobile health (mHealth) platforms can affect health behaviors but have not been rigorously tested in randomized trials. OBJECTIVES: We sought to evaluate the effectiveness of a pragmatic mHealth intervention in patients with heart failure (HF) ... Full text Link to item Cite

Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database.

Journal article Curr Probl Cardiol · November 2022 The trends of implantable cardioverter defibrillator (ICD) use in patients with a durable left ventricular assist device (LVAD) remain uncertain. We used the National Inpatient Sample to identify hospitalizations between 2009 and 2018 in which patients rec ... Full text Link to item Cite

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.

Journal article Eur Heart J · November 1, 2022 AIMS: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). M ... Full text Link to item Cite

Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.

Journal article Eur J Heart Fail · November 2022 Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state. Soluble guanylate cyclase (sGC) stimulator ... Full text Link to item Cite

Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019.

Journal article JACC Heart Fail · November 2022 BACKGROUND: The U.S. population is aging with concurrent increases in heart failure (HF) burden. However, HF-related mortality trends among adults ≥75 years have not been investigated. OBJECTIVES: The purpose of this study was to assess the trends and regi ... Full text Link to item Cite

Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry.

Journal article Circ Heart Fail · November 2022 BACKGROUND: Neighborhood socioeconomic status (SES) is associated with worse health outcomes, yet its relationship with in-hospital heart failure (HF) outcomes and quality metrics are underexplored. We examined the association between socioeconomic neighbo ... Full text Link to item Cite

Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial.

Journal article J Card Fail · October 2022 BACKGROUND: Death ascertainment can be challenging for pragmatic clinical trials that limit site follow-up activities to usual clinical care. METHODS AND RESULTS: We used blinded aggregate data from the ongoing ToRsemide comparison with furoSemide FOR Mana ... Full text Link to item Cite

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.

Journal article Circulation · September 13, 2022 BACKGROUND: Sodium-glucose cotransporter-2 inhibitors are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), but underlying mechanisms of benefit are not well defined. We sought to investigate the relationships betw ... Full text Link to item Cite

Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool.

Journal article J Card Fail · September 2022 Heart transplantation remains the gold-standard therapy for end-stage heart failure; the expected median survival range is 12-13 years. More than 30,000 heart transplants have been performed globally in the past decade alone. With advances in medical and s ... Full text Link to item Cite

Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial.

Journal article Am Heart J · September 2022 BACKGROUND: Clinical guidelines recommend titration of angiotensin converting enzyme inhibitors (ACEi) and beta-blockers among patients with heart failure with reduced ejection fraction (HFrEF) to maximally tolerated doses. Patient characteristics associat ... Full text Link to item Cite

Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019.

Journal article JAMA Cardiol · September 1, 2022 IMPORTANCE: There are limited data on mortality trends in young adults with heart failure (HF). OBJECTIVE: To study the trends in HF-related mortality among young adults. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used mortality ... Full text Link to item Cite

Catastrophic Disruptions in Clinical Trials.

Journal article Circulation · August 2, 2022 Full text Link to item Cite

Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.

Journal article J Card Fail · August 2022 BACKGROUND: Although a worsening heart failure event (WHFE) is associated with poor outcomes in patients with heart failure with reduced ejection fraction (HFrEF), it is unclear how guideline-directed medical therapy (GDMT) is used in this population compa ... Full text Link to item Cite

Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study.

Journal article J Card Fail · August 2022 BACKGROUND: Polyvascular disease is associated with increased mortality rates and decreased quality of life. Whether its prevalence or associated outcomes differ for patients hospitalized with heart failure with reduced vs preserved ejection fraction (HFrE ... Full text Link to item Cite

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.

Journal article Circulation · July 26, 2022 BACKGROUND: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chro ... Full text Link to item Cite

Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.

Journal article Circulation · July 12, 2022 BACKGROUND: Supervised aerobic exercise training (ET) is recommended for stable outpatients with heart failure (HF) with reduced ejection fraction (HFrEF). Frailty, a syndrome characterized by increased vulnerability and decreased physiologic reserve, is c ... Full text Link to item Cite

Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.

Journal article J Card Fail · July 2022 BACKGROUND: For patients hospitalized for heart failure with reduced ejection fraction (HFrEF), guidelines recommend optimization of medical therapy prior to discharge. The degree to which changes in medical therapy occur during hospitalizations for HFrEF ... Full text Link to item Cite

Fostering Belonging at JCF.

Journal article J Card Fail · July 2022 Full text Link to item Cite

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal article Cardiovasc Diabetol · June 27, 2022 BACKGROUND: To determine whether there were racial differences in short-term cardiometabolic responses to once-weekly exenatide (EQW) in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). METHODS: EXSCEL enrolled 14,752 patients with type 2 dia ... Full text Link to item Cite

Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events.

Journal article J Am Heart Assoc · June 7, 2022 Background The REHAB-HF (Rehabilitation Therapy in Older Acute Heart Failure Patients) trial showed that a novel, early, transitional, tailored, progressive, multidomain physical rehabilitation intervention improved physical function and quality of life in ... Full text Link to item Cite

Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure.

Journal article J Card Fail · June 2022 BACKGROUND: Worsening heart failure (HF) often requires hospitalization but in some cases may be managed in the outpatient or emergency department (ED) settings. The predictors and clinical significance of ED visits without admission vs hospitalization are ... Full text Link to item Cite

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.

Journal article Eur J Heart Fail · June 2022 AIMS: This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) b ... Full text Link to item Cite

In-Hospital Outcomes in Pregnancy After Heart Transplantation.

Journal article Am J Cardiol · June 1, 2022 Although the number of successful pregnancies in heart transplantation (HT) recipients is increasing, data regarding outcomes after delivery are limited. The 2010 to 2015 Nationwide Inpatient Sample was queried to identify index hospitalizations for delive ... Full text Link to item Cite

Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study.

Journal article Cardiovasc Diabetol · June 1, 2022 BACKGROUND: Cardiovascular prognosis related to type 2 diabetes may not be adequately captured by information on comorbid conditions such as obesity and hypertension. To inform the cardiovascular prognosis among diabetic individuals, we conducted phenotypi ... Full text Link to item Cite

Inclusion and diversity in clinical trials: Actionable steps to drive lasting change.

Journal article Contemp Clin Trials · May 2022 BACKGROUND: Improving diversity in clinical trials is essential in order to produce generalizable results. Although the importance of representation has become increasingly recognized, identifying strategies to approach this work remains elusive. This arti ... Full text Link to item Cite

Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.

Journal article JACC Heart Fail · May 2022 OBJECTIVES: The aim of this study was to assess trends in heart failure (HF) hospitalizations among young adults. BACKGROUND: Data are limited regarding clinical characteristics and outcomes of young adults hospitalized for HF. METHODS: The National Inpati ... Full text Link to item Cite

Sleep Breathing Disorders in Heart Failure.

Journal article Cardiol Clin · May 2022 Sleep-disordered breathing (SDB), including obstructive sleep apnea, central sleep apnea (CSA), and Cheyne-Stokes respiration, is common in patients with heart failure (HF) and associated with lower left ventricular ejection fraction (EF), increased arrhyt ... Full text Link to item Cite

Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study.

Journal article BMC Cardiovasc Disord · April 21, 2022 BACKGROUND: Left ventricular structure and function abnormalities may be an early marker of cardiomyopathy among African Americans with diabetes (DM) even in the absence of coronary artery disease (CAD), arrhythmia, valvular heart disease and end-stage ren ... Full text Link to item Cite

Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction.

Journal article Am Heart J · April 2022 BACKGROUND: Out-of-pocket (OOP) drug costs for Medicare Fee-for-Service (FFS) beneficiaries with heart failure with reduced ejection fraction (HFrEF) are not well characterized. This study evaluated Part D OOP spending by Medicare beneficiaries with chroni ... Full text Link to item Cite

Spirituality in Patients With Heart Failure.

Journal article JACC Heart Fail · April 2022 With advances in heart failure (HF) treatment, patients are living longer, putting further emphasis on quality of life (QOL) and the role of palliative care principles in their care. Spirituality is a core domain of palliative care, best defined as a dynam ... Full text Link to item Cite

Sex Differences in Heart Failure.

Journal article J Card Fail · March 2022 Heart failure (HF) continues to be a major contributor of morbidity and mortality for men and women alike, yet how the predisposition for, course and management of HF differ between men and women remains underexplored. Sex differences in traditional risk f ... Full text Link to item Cite

Dysglycemia and incident heart failure among blacks: The jackson heart study.

Journal article Am Heart J · March 2022 BACKGROUND: We aimed to investigate the associations of glycemic markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG] and glycemic status [normoglycemia, prediabetes and diabetes]) with incident heart failure (HF) and its subtypes, among Blacks. M ... Full text Link to item Cite

Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction.

Journal article Am Heart J · March 2022 BACKGROUND: Recent data suggest that patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure (WHF) have potential for greater benefit from newer HF therapies. We investigated characteristics and outcomes of patients w ... Full text Link to item Cite

Proteomic differences among patients with heart failure taking furosemide or torsemide.

Journal article Clin Cardiol · March 2022 BACKGROUND: Loop diuretics are commonly used for patients with heart failure (HF) but it remains unknown if one loop diuretic is clinically superior. HYPOTHESIS: Biomarkers and proteomics provide insight to how different loop diuretics may differentially a ... Full text Link to item Cite

Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women.

Journal article J Am Heart Assoc · March 2022 Background Associations between depression, incident heart failure (HF), and mortality are well documented in predominately White samples. Yet, there are sparse data from racial minorities, including those who are women, and depression is underrecognized a ... Full text Open Access Link to item Cite

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.

Journal article Nat Med · March 2022 The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patient ... Full text Link to item Cite

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.

Journal article J Am Coll Cardiol · February 8, 2022 With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of ... Full text Link to item Cite

Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience.

Journal article J Card Fail · February 2022 BACKGROUND: Palliative care (PC) in advanced heart failure (HF) aims to improve symptoms and quality of life (QOL), in part through medication management. The impact of PC on polypharmacy (>5 medications) remains unknown. METHODS AND RESULTS: We explored p ... Full text Link to item Cite

Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial.

Journal article JAMA Cardiol · February 1, 2022 IMPORTANCE: In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a novel 12-week rehabilitation intervention demonstrated significant improvements in validated measures of physical function, quality of life, and depression, ... Full text Link to item Cite

Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial.

Journal article J Palliat Med · February 2022 Introduction: Black patients have a higher incidence of heart failure (HF) and worse outcomes than white patients. Guidelines recommend palliative care for patients with advanced HF, but no studies have examined outcomes in a black patient cohort. Methods: ... Full text Link to item Cite

Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials.

Journal article Contemp Clin Trials · February 2022 Clinical trials are a cornerstone of modern medicine and form the backbone of evidence that is used to create evidence-based guidelines. Contemporary clinical trials have tended to be quite explanatory, assessing an intervention in ideal conditions with hi ... Full text Link to item Cite

Cardiovascular risk stratification in the noncardiac solid organ transplant candidate.

Journal article Curr Opin Organ Transplant · February 1, 2022 PURPOSE OF REVIEW: Solid organ transplantation (SOT) has become a widely accepted therapy for end-stage disease across the spectrum of thoracic and abdominal organs. With contemporary advances in medical and surgical therapies in transplantation, candidate ... Full text Link to item Cite

Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.

Journal article JACC Heart Fail · February 2022 OBJECTIVES: This study evaluated the association of transthyretin (TTR) gene variant, in which isoleucine substitutes for valine at position 122 (V142I), with cardiac structure, function, and heart failure (HF) risk among middle-aged Black adults. BACKGROU ... Full text Link to item Cite

Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF.

Journal article Am J Med · January 2022 BACKGROUND: Prior studies showed an attenuated response to exercise training among patients with heart failure and type 2 diabetes mellitus. We explored the interaction between diabetes status and a novel, transitional, tailored, progressive rehabilitation ... Full text Link to item Cite

Hypertensive Diseases in Pregnancy and Kidney Function Later in Life: The Genetic Epidemiology Network of Arteriopathy (GENOA) Study.

Journal article Mayo Clin Proc · January 2022 OBJECTIVE: To evaluate the relationship between hypertensive diseases in pregnancy and kidney function later in life. METHODS: We evaluated measured glomerular filtration rate (mGFR) using iothalamate urinary clearance in 725 women of the Genetic Epidemiol ... Full text Link to item Cite

Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study.

Journal article Circ Heart Fail · January 2022 BACKGROUND: Regulatory and clinical decisions involving health technologies require judgements about relative importance of their expected benefits and risks. We sought to quantify heart-failure patients' acceptance of therapeutic risks in exchange for imp ... Full text Link to item Cite

An evaluation of torsemide in patients with heart failure and renal disease.

Journal article Expert Rev Cardiovasc Ther · January 2022 INTRODUCTION: Torsemide is a loop diuretic that inhibits the Na+/K+/2Cl- cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated diuresis. While furosemide remains the dominant ... Full text Link to item Cite

The JCF Reviewer Mentorship Program.

Journal article J Card Fail · January 2022 Full text Link to item Cite

Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry.

Journal article J Card Fail · December 2021 BACKGROUND: In the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial, vericiguat reduced the risk of mortality due to cardiovascular problems and of hospitalization due to heart failure (HF) among patien ... Full text Link to item Cite

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.

Journal article JACC Heart Fail · December 2021 OBJECTIVES: The authors sought to investigate associations between sacubitril/valsartan adherence and clinical outcomes after hospitalization for heart failure with reduced ejection fraction (HFrEF). BACKGROUND: Sacubitril/valsartan improves outcomes in HF ... Full text Link to item Cite

Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Journal article Atherosclerosis · December 2021 BACKGROUND AND AIMS: Polyvascular disease is an independent predictor of major adverse cardiovascular events (MACE). The relationship between the number of diseased arterial beds and MACE is unknown. How MACE risk changes in individuals with type 2 diabete ... Full text Link to item Cite

Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.

Journal article Circ Heart Fail · December 2021 BACKGROUND: Bedside evaluation of congestion is a mainstay of heart failure (HF) management. Whether detected physical examination signs have changed over time as obesity prevalence has increased in HF populations, or if the associated prognosis differs fo ... Full text Link to item Cite

JCF Year-In-Review 2021 and the Path Forward.

Journal article J Card Fail · December 2021 Full text Link to item Cite

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.

Journal article J Am Coll Cardiol · November 16, 2021 Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on ... Full text Link to item Cite

Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease.

Journal article J Card Fail · November 2021 BACKGROUND: Greater variability in the estimated glomerular filtration rate (eGFR) is associated with higher mortality in patients with chronic kidney disease (CKD). Heart failure (HF) is common in CKD and may increase variability through changes in hemody ... Full text Link to item Cite

Drugs of Abuse and Heart Failure.

Journal article J Card Fail · November 2021 Substance use is common among those with heart failure (HF) and is associated with worse clinical outcomes. Alcohol, tobacco, cannabis, and cocaine are commonly abused substances that can contribute to the development and worsening of HF. Heavy alcohol con ... Full text Link to item Cite

Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study).

Journal article Am J Cardiol · November 1, 2021 An expanding number of therapies are now indicated for comorbidity management in heart failure with preserved ejection fraction (HFpEF). Whether comorbidity burdens differ for patients with HFpEF who are hospitalized for acute decompensated heart failure ( ... Full text Link to item Cite

Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction.

Journal article JACC Basic Transl Sci · November 2021 Although there is an established bidirectional relationship between heart failure with reduced ejection fraction and liver disease, the association between heart failure with preserved ejection fraction (HFpEF) and liver diseases, such as nonalcoholic fatt ... Full text Link to item Cite

Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction.

Journal article CJC Open · November 2021 BACKGROUND: Prior studies suggest similar long-term mortality rates for patients with heart failure (HF) with preserved ejection fraction (HFpEF) vs reduced ejection fraction. However, although coronary heart disease (CHD) is associated with worse prognosi ... Full text Link to item Cite

Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure.

Journal article J Cardiovasc Transl Res · October 2021 We examined the relationship between pain severity and outcomes in patients with heart failure with reduced ejection fraction (HFrEF) in the HF-ACTION randomized controlled trial. Trends of health-related quality of life (HRQoL) measures grouped by patient ... Full text Link to item Cite

Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.

Journal article Diabet Med · October 2021 AIMS: Although models exist to predict amputation among people with type 2 diabetes with foot ulceration or infection, we aimed to develop a prediction model for a broader range of major adverse limb events (MALE)-including gangrene, revascularization and ... Full text Link to item Cite

Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction.

Journal article JACC Heart Fail · October 2021 OBJECTIVES: This study assessed for treatment interactions by ejection fraction (EF) subgroup (≥45% [heart failure with preserved ejection fraction (HFpEF); vs <45% [heart failure with reduced ejection fraction (HFrEF)]). BACKGROUND: The REHAB-HF trial sho ... Full text Open Access Link to item Cite

Physical Rehabilitation in Patients with Heart Failure.

Journal article N Engl J Med · September 30, 2021 Full text Link to item Cite

Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review.

Journal article J Am Coll Cardiol · September 14, 2021 Exercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals. The recent recognition that HFpEF is likely a systemic, multiorgan diso ... Full text Link to item Cite

Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.

Journal article Am Heart J · September 2021 Cardiovascular (CV) outcome studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shifted the paradigm of type 2 diabetes management given their benefits regarding a reduction in major adverse CV events. However, the relationship between GL ... Full text Link to item Cite

Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends.

Journal article J Card Fail · September 2021 BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) continues to increase in prevalence with a 50% mortality rate within 3 years of diagnosis, but lacking effective evidence-based therapies. Specific echocardiographic markers are not typical ... Full text Link to item Cite

Physical Functioning in Heart Failure With Preserved Ejection Fraction.

Journal article J Card Fail · September 2021 Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent, yet interventions and therapies to improve outcomes remain limited. There has been increasing attention towards the impact of comorbidities and physical functioning (PF) on p ... Full text Link to item Cite

Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure.

Journal article Am Heart J · September 2021 BACKGROUND: Decongestion is a primary goal during hospitalizations for decompensated heart failure (HF). However, data surrounding the preferred route and strategy of diuretic administration are limited with varying results in prior studies. METHODS: This ... Full text Link to item Cite

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.

Journal article Circ Heart Fail · September 2021 BACKGROUND: Randomized controlled trials (RCTs) often target enrollment of patients with demographics and outcomes less representative of the broader population of interest. To provide context for the VICTORIA trial (Vericiguat Global Study in Subjects Wit ... Full text Link to item Cite

Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure.

Journal article Circ Heart Fail · September 2021 BACKGROUND: The Kansas City Cardiomyopathy Questionnaire (KCCQ) has been psychometrically evaluated in multiple heart failure (HF) populations, but the comparability of its psychometric properties between men and women is unknown. METHODS: Data from 3 clin ... Full text Link to item Cite

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.

Journal article J Am Heart Assoc · August 17, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real-world US practice ... Full text Link to item Cite

Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.

Journal article ESC Heart Fail · August 2021 AIMS: Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. ... Full text Link to item Cite

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.

Journal article JACC Heart Fail · August 2021 OBJECTIVES: Using latent class analysis (LCA) of EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), this study identified distinct phenotypes in subjects with type 2 diabetes (T2D) and cardi ... Full text Link to item Cite

Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.

Journal article J Card Fail · August 2021 BACKGROUND: We investigated associations between timing of sacubitril/valsartan initiation and postdischarge adherence among patients hospitalized for heart failure with reduced ejection fraction (HFrEF). Clinical trials support initiation of sacubitril/va ... Full text Link to item Cite

Reply: Pragmatic Clinical Trials: The Big Picture.

Journal article JACC Heart Fail · August 2021 Full text Link to item Cite

Causes of hospitalization in the USA between 2005 and 2018.

Journal article Eur Heart J Open · August 2021 In this report, we identify the 10 most common causes of hospitalizations in the USA in 2005-2018 using the discharge data from the National Inpatient Sample database. We show that sepsis has been the leading cause of hospitalizations in the USA followed b ... Full text Link to item Cite

Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study.

Journal article J Am Heart Assoc · July 20, 2021 Background Visceral adipose tissue (VAT) is associated with incident heart failure (HF) and HF with preserved ejection fraction, yet it is unknown how pericardial and abdominal adiposity affect HF and mortality risks in Black individuals. We examined the a ... Full text Link to item Cite

Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.

Journal article N Engl J Med · July 15, 2021 BACKGROUND: Older patients who are hospitalized for acute decompensated heart failure have high rates of physical frailty, poor quality of life, delayed recovery, and frequent rehospitalizations. Interventions to address physical frailty in this population ... Full text Link to item Cite

A Case for Re-Gifting.

Journal article JACC Case Rep · July 7, 2021 Many patients die while waiting for a heart transplant. Therefore, it is vital that all suitable organs are used for transplantation. We present a case of an allograft that was transplanted twice and outline considerations regarding tissue typing, the impa ... Full text Link to item Cite

The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure.

Journal article J Card Fail · July 2021 BACKGROUND: Elevated plasma interleukin-6 (IL-6) concentrations are frequently observed in patients with acute heart failure (AHF). However, the predictive value of serial IL-6 measurements beyond brain natriuretic peptide (BNP) remains poorly characterize ... Full text Link to item Cite

Relationship of physical function with quality of life in older patients with acute heart failure.

Journal article J Am Geriatr Soc · July 2021 BACKGROUND: Older patients with acute decompensated heart failure (ADHF) have severely impaired physical function (PF) and quality of life (QOL). However, relationships between impairments in PF and QOL are unknown but are relevant to clinical practice and ... Full text Open Access Link to item Cite

Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure.

Journal article JACC Heart Fail · July 2021 OBJECTIVES: The purpose of this study was to assess temporal trends and factors associated with cardiac rehabilitation (CR) enrollment and participation among Medicare beneficiaries after the 2014 Medicare coverage expansion. BACKGROUND: CR improves exerci ... Full text Link to item Cite

Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults.

Journal article JACC Heart Fail · July 2021 OBJECTIVES: This study sought to evaluate the independent associations and interactions between high-sensitivity cardiac troponin I (hs-cTnI) and physical activity (PA) with risk of heart failure (HF) subtypes, HF with preserved ejection fraction (HFpEF) a ... Full text Link to item Cite

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.

Journal article J Card Fail · June 24, 2021 BACKGROUND: The prediction of outcomes in patients with heart failure (HF) may inform prognosis, clinical decisions regarding treatment selection, and new trial planning. The VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Frac ... Full text Link to item Cite

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.

Journal article J Card Fail · June 24, 2021 BACKGROUND: The prediction of outcomes in patients with heart failure (HF) may inform prognosis, clinical decisions regarding treatment selection, and new trial planning. The VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Frac ... Full text Link to item Cite

Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis.

Journal article Circulation · June 15, 2021 BACKGROUND: Heart failure (HF) risk and the underlying risk factors vary by race. Traditional models for HF risk prediction treat race as a covariate in risk prediction and do not account for significant parameters such as cardiac biomarkers. Machine learn ... Full text Link to item Cite

The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial.

Journal article J Card Fail · June 2021 BACKGROUND: In a randomized control trial, Palliative Care in Heart Failure (PAL-HF) improved heart failure-related quality of life, though cost-effectiveness remains unknown. The aim of this study was to evaluate the cost-effectiveness of the PAL-HF trial ... Full text Link to item Cite

Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.

Journal article Curr Heart Fail Rep · June 2021 PURPOSE OF REVIEW: Multiple newer medications benefit patients with heart failure with reduced ejection fraction (HFrEF). While these therapies benefit the broad population with HFrEF, the efficacy and safety of these therapies have been less well characte ... Full text Link to item Cite

Thoughtful selection and use of scientific terms in clinical research: the case of 'pragmatic' trials.

Journal article J Investig Med · June 2021 Clinical research is a discipline prone to the use of technical terms that may be particularly at risk for misunderstanding given the complex interpretation that is required. In this century, what is happening with the word 'pragmatic' when describing a ra ... Full text Link to item Cite

Egg Consumption and Risk of Cardiovascular Disease: a Critical Review

Journal article Current Emergency and Hospital Medicine Reports · June 2021 Full text Cite

Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction.

Journal article J Am Geriatr Soc · May 2021 BACKGROUND/OBJECTIVES: Obesity increases with age, is disproportionately prevalent in black populations, and is associated with heart failure with preserved ejection fraction (HFpEF). An "obesity paradox," or improved survival with obesity, has been report ... Full text Link to item Cite

Acute cardiovascular hospitalizations and illness severity before and during the COVID-19 pandemic.

Journal article Clin Cardiol · May 2021 BACKGROUND: Cardiovascular disease (CVD) hospitalizations declined worldwide during the COVID-19 pandemic. It is unclear how shelter-in-place orders affected acute CVD hospitalizations, illness severity, and outcomes. HYPOTHESIS: COVID-19 pandemic was asso ... Full text Link to item Cite

Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.

Journal article JACC Heart Fail · May 2021 Randomized clinical trials are the foundation of evidence-based medicine and central to practice guidelines and patient care decisions. Nonetheless, randomized trials in heart failure (HF) populations have become increasingly difficult to conduct and are f ... Full text Link to item Cite

Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.

Journal article JACC Heart Fail · May 2021 OBJECTIVES: The goal of this study was to evaluate differences in clinical and patient-reported outcomes between women and men hospitalized for acute HF. BACKGROUND: Among patients hospitalized for heart failure (HF), it is unclear if symptom burden, respo ... Full text Link to item Cite

Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.

Journal article Circ Heart Fail · May 2021 BACKGROUND: Iron deficiency (ID) has a prevalence of ≈40% to 50% among patients in heart failure (HF) with reduced ejection fraction and is associated with worse prognosis. Several trials demonstrated that intravenous ferric carboxymaltose leads to early a ... Full text Link to item Cite

Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study.

Journal article J Am Heart Assoc · April 6, 2021 Background Although Black adults are more likely to die from coronary heart disease (CHD) compared with White adults, few studies have examined the relationship between cigarette smoking and CHD risk among Black adults. We evaluated the relationship betwee ... Full text Link to item Cite

Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure.

Journal article JACC Heart Fail · April 2021 OBJECTIVES: The authors estimated changes of stressed blood volume (SBV) induced by splanchnic nerve block (SNB) in patients with either decompensated or ambulatory heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The splanchnic vascular c ... Full text Link to item Cite

Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.

Journal article Circ Heart Fail · April 2021 BACKGROUND: Hospitalization for heart failure (HF) is associated with increased risk of death among patients with chronic HF. The degree to which hospitalization for HF is a distinct biologic entity with independent prognostic value versus a marker of high ... Full text Link to item Cite

Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure.

Journal article J Card Fail · March 2021 BACKGROUND: Older adults with acute decompensated heart failure have persistently poor clinical outcomes. Cognitive impairment (CI) may be a contributing factor. However, the prevalence of CI and the relationship of cognition with other patient-centered fa ... Full text Link to item Cite

Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure.

Journal article J Card Fail · March 2021 BACKGROUND: Prior analyses suggest an association between formula-based plasma volume (PV) estimates and outcomes in heart failure (HF). We assessed the association between estimated PV status by the Duarte-ePV and Kaplan Hakim (KH-ePVS) formulas, and in-h ... Full text Link to item Cite

Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.

Journal article Am Heart J · March 2021 Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate ... Full text Link to item Cite

Differences between patients with cardiovascular disease and cancer referred for palliative care.

Journal article Am Heart J · March 2021 Our analysis from a national registry shows that compared to cancer, cardiovascular disease patients referred to palliative care are a decade older, have worse functional status and clinician-estimated prognosis. Both groups have very high symptom burden, ... Full text Link to item Cite

Body surface area and medication dosing in patients with heart failure with reduced ejection fraction.

Journal article Trends Cardiovasc Med · February 2021 Multiple medications are proven to reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), but data regarding personalized approaches to optimize medication dosing remain limited. Current treatment guidelines r ... Full text Link to item Cite

Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis.

Journal article ESC Heart Fail · February 2021 AIMS: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition, and tissue congestion manifested by oedema is not present in all patients. We compared clinical characteristics, exercise capacity, and outcomes in patients with HFp ... Full text Link to item Cite

OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device.

Journal article ASAIO J · February 1, 2021 OptiVol (Medtronic PLC, Minneapolis, MN) is a diagnostic feature of some cardiac implantable electronic devices (CIEDs) based on changes in thoracic impedance (TI) over time. Changes in TI can predict heart failure (HF) hospitalizations and mortality in HF ... Full text Link to item Cite

Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event.

Journal article J Med Econ · 2021 AIMS: The study compared quality outcomes, resource utilization, and costs in Medicare beneficiaries with chronic heart failure with reduced ejection fraction (HFrEF) with and without a worsening heart failure event (WHFE). METHODS: This retrospective obse ... Full text Link to item Cite

Sleep quality, depressive symptoms, and transplant outcomes: Follow-up analyses from the ADAPT prospective pilot study.

Journal article Gen Hosp Psychiatry · 2021 BACKGROUND: Previous studies suggested that depressive symptoms and sleep quality may be important for long-term clinical outcomes following cardiothoracic transplant. Few studies, however, have systematically examined objective markers of these behavioral ... Full text Link to item Cite

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF.

Journal article J Am Heart Assoc · December 15, 2020 Background Ultrafiltration is not commonly used because of higher incidence of worsening renal function without improved decongestion. We examined differential outcomes of high versus low fluid removal and preserved versus reduced ejection fraction (EF) in ... Full text Open Access Link to item Cite

Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials.

Journal article Stat Med · December 10, 2020 Cluster randomized trials (CRTs) refer to experiments with randomization carried out at the cluster or the group level. While numerous statistical methods have been developed for the design and analysis of CRTs, most of the existing methods focused on test ... Full text Link to item Cite

PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.

Journal article Am Heart J · December 2020 BACKGROUND: In PARADIGM-HF, sacubitril/valsartan improved quality of life (QOL) versus enalapril in heart failure with reduced ejection fraction (HFrEF), yet limited data are available regarding QOL changes after sacubitril/valsartan initiation in routine ... Full text Link to item Cite

Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX.

Journal article Am J Med · December 2020 PURPOSE: We aimed to 1) describe characteristics of patients with heart failure with preserved ejection fraction (HFpEF) enrolled in RELAX stratified by normal or elevated baseline serum uric acid (sUA) level; 2) evaluate the association between sUA level ... Full text Link to item Cite

Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study).

Journal article Am J Cardiol · December 1, 2020 There is no clear consensus on a lower cutoff value for normal left ventricular ejection fraction (EF) and the prognostic implications of low normal EF (LNEF) are poorly understood, particularly in Blacks. Therefore, we investigated the association of LNEF ... Full text Link to item Cite

Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.

Journal article Diabetes Obes Metab · December 2020 The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in patients with type 2 diabetes at high cardiovascular risk are modest or neutral. However, GLP-1RAs may confer clinical benefits in those at high risk of progressive re ... Full text Link to item Cite

Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center.

Journal article Am Heart J · December 2020 UNLABELLED: Smoking is associated with incident heart failure (HF), yet limited data are available exploring the association between smoking status and long-term outcomes in HF with reduced vs. preserved ejection fraction (i.e., HFrEF vs. HFpEF). METHODS: ... Full text Link to item Cite

In-hospital outcomes after bariatric surgery in patients with heart failure.

Journal article Am Heart J · December 2020 Based on the largest publicly available all-payer inpatient database in the United States, this study sought to evaluate real-world outcomes after bariatric surgery among patients with heart failure. ... Full text Link to item Cite

Patient-Centered Measures of Treatment Benefit.

Journal article JACC Heart Fail · December 2020 Full text Link to item Cite

Suboptimal sleep and incident cardiovascular disease among African Americans in the Jackson Heart Study (JHS).

Journal article Sleep Med · December 2020 BACKGROUND: Suboptimal sleep, including insufficient/long sleep duration and poor sleep quality, is a risk factor for cardiovascular disease (CVD) common but there is little information among African Americans, a group with a disproportionate CVD burden. T ... Full text Link to item Cite

Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.

Journal article J Am Coll Cardiol · November 17, 2020 The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The Heart Failure Academic ... Full text Link to item Cite

Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure.

Journal article Am Heart J · November 2020 Machine learning and artificial intelligence are generating significant attention in the scientific community and media. Such algorithms have great potential in medicine for personalizing and improving patient care, including in the diagnosis and managemen ... Full text Link to item Cite

Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.

Journal article JAMA Netw Open · October 1, 2020 IMPORTANCE: Obesity is a global health challenge and a risk factor for atherosclerotic cardiovascular disease (ASVCD). Performance of the pooled cohort equations (PCE) for ASCVD risk by body mass index (BMI; calculated as weight in kilograms divided by hei ... Full text Link to item Cite

Regional adiposity and heart failure with preserved ejection fraction.

Journal article Eur J Heart Fail · September 2020 The role of obesity in the pathogenesis of heart failure (HF), and in particular HF with preserved ejection fraction (HFpEF), has drawn significant attention in recent years. The prevalence of both obesity and HFpEF has increased worldwide over the past de ... Full text Link to item Cite

Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device.

Journal article Ann Thorac Surg · August 2020 BACKGROUND: Patients with end-stage heart failure are increasingly being bridged to heart transplant (BTT) with mechanical circulatory support; however the association between a left ventricular assist device (LVAD) BTT strategy and posttransplant renal ou ... Full text Link to item Cite

A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF).

Journal article J Cardiovasc Transl Res · August 2020 Patients hospitalized for heart failure (HF) remain at high risk for early readmission. A post hoc analysis was performed of the biomarker substudy of the ASCEND-HF trial. An in-hospital congestion score was derived using orthopnea, pedal edema, and NT-pro ... Full text Link to item Cite

Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

Journal article Eur J Heart Fail · August 2020 AIMS: In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care [placebo or continued low-dose spironolactone (25 mg dail ... Full text Link to item Cite

Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.

Journal article JAMA Cardiol · August 1, 2020 IMPORTANCE: Clinical and economic consequences of statin treatment guidelines supplemented by targeted coronary artery calcium (CAC) assessment have not been evaluated in African American individuals, who are at increased risk for atherosclerotic cardiovas ... Full text Link to item Cite

Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations.

Journal article Am Heart J · August 2020 UNLABELLED: Little is known about the impact of accountable care organizations (ACO) on hospitalized heart failure (HF) patients, a high-cost and high-risk population. OBJECTIVE: We linked Medicare fee-for-service claims from 2013 to 2015 with data from Am ... Full text Link to item Cite

Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Journal article Am Heart J · August 2020 Cardiovascular disease has an increased prevalence among patients with idiopathic pulmonary fibrosis (IPF). Cardiovascular disease and IPF share similar symptoms with overlapping demographics and risk factors for disease development. Common cellular mediat ... Full text Link to item Cite

Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review.

Journal article J Am Coll Cardiol · July 28, 2020 The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual ... Full text Link to item Cite

Randomization versus Real-World Evidence.

Journal article N Engl J Med · July 23, 2020 Full text Link to item Cite

Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance.

Journal article Circulation · July 21, 2020 BACKGROUND: Patients with heart failure (HF) have multiple coexisting comorbidities. The temporal trends in the burden of comorbidities and associated risk of mortality among patients with HF with preserved ejection fraction (HFpEF) and HF with reduced eje ... Full text Link to item Cite

Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout.

Journal article Am J Cardiol · July 15, 2020 Hyperuricemia and gout are common in patients with heart failure (HF) and are associated with poor outcomes. Data describing hyperuricemia and gout in patients with HF with preserved ejection fraction (HFpEF) are limited. We used data from the Duke Univers ... Full text Link to item Cite

Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis.

Journal article JACC Heart Fail · July 2020 BACKGROUND: An early report of recipient heart transplantation outcomes under the new U.S. heart allocation system introduced in late 2018 found a lower post-transplant survival rate compared with that of the prior system. OBJECTIVES: The aim of this study ... Full text Link to item Cite

A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.

Journal article Am Heart J · July 2020 The infection caused by severe acute respiratory syndrome coronavirus-2, or COVID-19, can result in myocardial injury, heart failure, and arrhythmias. In addition to the viral infection itself, investigational therapies for the infection can interact with ... Full text Link to item Cite

Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study.

Journal article Pregnancy Hypertens · July 2020 BACKGROUND: Hypertensive diseases in pregnancy have been associated with altered cardiac structure and function, yet these associations have not been systematically investigated in larger populations including African Americans. We evaluated the relationsh ... Full text Link to item Cite

Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation.

Journal article Circ Heart Fail · July 2020 Biomarkers have a well-defined role in the diagnosis and management of chronic heart failure, but their role in patients with left ventricular assist devices and cardiac transplant is uncertain. In this review, we summarize the available literature in this ... Full text Link to item Cite

Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study.

Journal article J Am Heart Assoc · June 16, 2020 Background Blacks are disproportionately affected by stroke compared with whites; however, less is known about the relationship between stroke and cigarette smoking in blacks. Therefore, we evaluated the relationship between cigarette smoking and all incid ... Full text Link to item Cite

The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.

Journal article Eur J Heart Fail · June 2020 AIMS: Non-cardiac comorbidities are highly prevalent in patients with heart failure (HF). Our objective was to define the association between non-cardiac comorbidity burden and clinical outcomes, costs of care, and length of stay within a large randomized ... Full text Link to item Cite

Increasing the United States heart transplant donor pool with donation after circulatory death.

Journal article J Thorac Cardiovasc Surg · May 2020 DCD heart donation has the potential to significantly increase the pool of available donor allografts in the US, by as much as 30%, and will lead to a substantial decrease in waiting list mortality. ... Full text Link to item Cite

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.

Journal article Am Heart J · May 2020 BACKGROUND: Ivabradine is guideline-recommended to reduce heart failure (HF) hospitalization in patients with stable chronic HF with reduced ejection fraction (EF). Ivabradine initiation following acute HF has had limited evaluation, and there are few rand ... Full text Link to item Cite

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Journal article Circ Heart Fail · May 2020 BACKGROUND: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide v ... Full text Link to item Cite

Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.

Journal article Circulation · April 28, 2020 BACKGROUND: EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equipoise. Consequently, greater drop-in of open-lab ... Full text Link to item Cite

Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis.

Journal article J Thorac Cardiovasc Surg · April 2020 OBJECTIVES: We hypothesized that an increased duration of donor brain death may worsen survival following orthotopic heart transplantation. METHODS: The United Network for Organ Sharing Registry was queried for first-time, adult recipients of heart transpl ... Full text Link to item Cite

Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial.

Journal article Circ Heart Fail · April 2020 BACKGROUND: Palliative care improves quality of life in patients with heart failure. Whether men and women with heart failure derive similar benefit from palliative care interventions remains unknown. METHODS: In a secondary analysis of the PAL-HF trial (P ... Full text Link to item Cite

Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.

Journal article JAMA Cardiol · March 1, 2020 IMPORTANCE: There are major gaps in use of guideline-directed medical therapy (GDMT) for patients with heart failure (HF). Patient-reported data outlining patient goals and preferences associated with GDMT are not available. OBJECTIVE: To survey patients w ... Full text Link to item Cite

Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.

Journal article Diabetes Care · March 2020 OBJECTIVE: We sought to confirm a bidirectional association between severe hypoglycemic events (SHEs) and cardiovascular (CV) event risk and to characterize individuals at dual risk. RESEARCH DESIGN AND METHODS: In a post hoc analysis of 14,752 Exenatide S ... Full text Link to item Cite

Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.

Journal article Am Heart J · March 2020 BACKGROUND: The rate-limiting step in STEMI diagnosis often is the availability of a 12-lead electrocardiogram (ECG) and its interpretation. The potential may exist to speed the availability of 12-lead ECG information by using commonly available mobile tec ... Full text Open Access Link to item Cite

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

Journal article Diabetes Care · February 2020 OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean ... Full text Link to item Cite

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal article Diabetes Care · February 2020 OBJECTIVE: To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event ... Full text Link to item Cite

Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions.

Journal article Expert Rev Cardiovasc Ther · February 2020 Introduction: Both heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF) independently cause significant morbidity and mortality. The two conditions commonly coexist and AF in the setting of HFrEF is associated with worse mortal ... Full text Link to item Cite

Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example.

Journal article Contemporary clinical trials · January 2020 Individual-level baseline covariate imbalance could happen more frequently in cluster randomized trials, and may influence the observed treatment effect. Using computer and real-data simulations, this paper quantifies the extent and impact of covariate imb ... Full text Cite

Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.

Journal article Am Heart J · January 2020 BACKGROUND: Obesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship betw ... Full text Link to item Cite

Sleep Breathing Disorders in Heart Failure.

Journal article Heart Fail Clin · January 2020 Sleep-disordered breathing (SDB), including obstructive sleep apnea, central sleep apnea (CSA), and Cheyne-Stokes respiration, is common in patients with heart failure (HF) and associated with lower left ventricular ejection fraction (EF), increased arrhyt ... Full text Link to item Cite

Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis.

Journal article Circulation · December 17, 2019 BACKGROUND: Risk for atherosclerotic cardiovascular disease was a novel consideration for antihypertensive medication initiation in the 2017 American College of Cardiology/American Heart Association Blood Pressure (BP) guideline. Whether biomarkers of chro ... Full text Link to item Cite

Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis.

Journal article J Clin Sleep Med · December 15, 2019 STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective ... Full text Link to item Cite

Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults.

Journal article JAMA Cardiol · December 1, 2019 IMPORTANCE: The prevalence of hypertension and the risk for hypertension-related cardiovascular disease (CVD) are high among black adults. The population-attributable risk (PAR) accounts for both prevalence and excess risk of disease associated with a risk ... Full text Link to item Cite

International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.

Journal article Am Heart J · December 2019 International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14 ... Full text Open Access Link to item Cite

Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction.

Journal article JACC Heart Fail · December 2019 OBJECTIVES: This study sought to determine whether age modifies the impact of key comorbidities on clinical outcomes for patients with heart failure with reduced ejection fraction (HFrEF). BACKGROUND: Comorbidities impact outcomes in HFrEF. However, the ef ... Full text Link to item Cite

Frailty Among Older Decompensated Heart Failure Patients: Prevalence, Association With Patient-Centered Outcomes, and Efficient Detection Methods.

Journal article JACC Heart Fail · December 2019 OBJECTIVES: This study sought to assess the prevalence of frailty, its associations with physical function, quality of life (QoL), cognition, and depression and to investigate more efficient methods of detection in older patients hospitalized with acute de ... Full text Link to item Cite

Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?

Journal article Curr Heart Fail Rep · December 2019 PURPOSE OF REVIEW: Explore controversial biomarker-guided management of patients with heart failure (HF) with reduced ejection fraction. RECENT FINDINGS: Natriuretic peptides (e.g., BNP, NT-proBNP) are elevated in HF as a result of end-diastolic stress and ... Full text Link to item Cite

Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms.

Journal article Circ Cardiovasc Interv · December 2019 BACKGROUND: The Food and Drug Administration's Center for Drugs and Radiological Health issued Guidance in 2016 on generating patient preference information to aid evaluation of medical devices. Consistent with this guidance, we aimed to provide quantitati ... Full text Link to item Cite

Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.

Journal article Circ Cardiovasc Interv · December 2019 BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater ... Full text Link to item Cite

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Journal article Circulation · November 12, 2019 BACKGROUND: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baselin ... Full text Link to item Cite

Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis.

Journal article J Clin Sleep Med · November 5, 2019 STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective ... Link to item Cite

Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study.

Journal article Clin Transplant · November 2019 BACKGROUND: Physical inactivity and depressive symptoms following cardiothoracic transplantation are recognized as potentially modifiable psychosocial factors to improve clinical outcomes. However, few studies have prospectively assessed these in ambulator ... Full text Link to item Cite

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Journal article JACC Heart Fail · November 2019 OBJECTIVES: This study sought to determine the degree to which U.S. patients enrolled in a heart failure (HF) trial represent patients in routine U.S. clinical practice according to race and sex. BACKGROUND: Black patients and women are frequently under-re ... Full text Link to item Cite

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Journal article Circulation · October 29, 2019 BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well- ... Full text Link to item Cite

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Journal article Cardiovasc Diabetol · October 22, 2019 BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical ou ... Full text Link to item Cite

Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial.

Journal article Can J Cardiol · September 2019 BACKGROUND: Acute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone. METHODS: The Aldosterone Targeted Neuroh ... Full text Link to item Cite

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.

Journal article Circulation · August 13, 2019 Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden o ... Full text Link to item Cite

Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

Journal article J Card Fail · August 2019 Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden o ... Full text Link to item Cite

The continuous heart failure spectrum: moving beyond an ejection fraction classification.

Journal article Eur Heart J · July 1, 2019 Randomized clinical trials initially used heart failure (HF) patients with low left ventricular ejection fraction (LVEF) to select study populations with high risk to enhance statistical power. However, this use of LVEF in clinical trials has led to oversi ... Full text Link to item Cite

Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.

Journal article Am Heart J · June 2019 BACKGROUND: Emerging data suggest that neck circumference (NC) is associated with cardiometabolic risk factors. Limited research is available regarding the association between NC and cardiovascular outcomes in African Americans. METHODS: Using data from th ... Full text Link to item Cite

Clinical profiles in acute heart failure: an urgent need for a new approach.

Journal article ESC Heart Fail · June 2019 Acute heart failure (HF) is a major public health concern, responsible for >26 million hospitalizations per year worldwide. Many trials have investigated new therapeutic options for acute HF, with most revealing equivocal results. Successful innovations in ... Full text Link to item Cite

10-Year Risk Equations for Incident Heart Failure in the General Population.

Journal article J Am Coll Cardiol · May 21, 2019 BACKGROUND: Primary prevention strategies to mitigate the burden of heart failure (HF) are urgently needed. However, no validated risk prediction tools are currently in use. OBJECTIVES: This study sought to derive 10-year risk equations of developing incid ... Full text Link to item Cite

Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care.

Journal article JAMA Netw Open · May 3, 2019 IMPORTANCE: Use of palliative care (PC) for patients with cardiovascular disease (CVD) has increased recently. However, it is unknown if patients are receiving earlier referrals to PC. OBJECTIVE: To assess characteristics and trends of patients with CVD re ... Full text Link to item Cite

Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial.

Journal article Am Heart J · May 2019 Heart failure (HF) and diabetes mellitus (DM) are major public health issues that place significant burden on patients and health care systems. Patients with both HF and DM are at higher risk of adverse cardiovascular and HF outcomes than those with either ... Full text Link to item Cite

Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease.

Journal article JACC Heart Fail · May 2019 Large randomized clinical trials (RCT) supporting guidelines for the management of heart failure with reduced ejection fraction (HFrEF) have typically excluded patients with advanced chronic kidney disease (CKD). Patients with concomitant advanced CKD and ... Full text Link to item Cite

Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial.

Journal article J Cardiovasc Med (Hagerstown) · April 2019 BACKGROUND: The IRONOUT-HF trial previously demonstrated that oral iron supplementation minimally increased iron stores and did not improve exercise capacity in patients with heart failure with a reduced ejection fraction (HFrEF) and iron deficiency. METHO ... Full text Link to item Cite

Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices.

Journal article J Palliat Med · April 2019 Advanced heart failure (HF) is a common condition that leads to significant suffering for patients and their families. Left ventricular assist devices (LVADs) can improve both the quantity and quality of life for those suffering with advanced HF. Palliativ ... Full text Link to item Cite

Correction.

Journal article BMJ · April 1, 2019 Full text Link to item Cite

Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality.

Journal article JAMA · March 19, 2019 IMPORTANCE: Cholesterol is a common nutrient in the human diet and eggs are a major source of dietary cholesterol. Whether dietary cholesterol or egg consumption is associated with cardiovascular disease (CVD) and mortality remains controversial. OBJECTIVE ... Full text Link to item Cite

Cigarette Smoking and Subclinical Peripheral Arterial Disease in Blacks of the Jackson Heart Study.

Journal article J Am Heart Assoc · February 5, 2019 Background Prevalence of peripheral artery disease ( PAD ) is significantly higher among blacks as compared with non-Hispanic whites, but the role of cigarette smoking in PAD is understudied in blacks. We aimed to evaluate the relationship between cigarett ... Full text Link to item Cite

Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.

Journal article J Am Heart Assoc · February 5, 2019 Background The angiotensin-receptor/neprilysin inhibitor ( ARNI ) sacubitril/valsartan reduces hospitalization and mortality for patients with heart failure with reduced ejection fraction. However, adoption of ARNI into clinical practice has been slow. Fac ... Full text Link to item Cite

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Journal article Diabetes Care · February 2019 OBJECTIVE: The sodium-glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin reduce the incidence of major adverse cardiovascular events (MACE), all-cause mortality (ACM), and renal events in cardiovascular outcomes trials, with observ ... Full text Link to item Cite

Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes.

Journal article Clin Cardiol · February 2019 BACKGROUND: When used in appropriately selected heart failure (HF) patients, cardiac resynchronization therapy (CRT) reduces mortality and hospitalization. It is not understood whether CRT implantation during hospitalization for HF is associated with simil ... Full text Link to item Cite

Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.

Journal article Eur J Heart Fail · January 2019 AIMS: A 5-point change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) is commonly considered to be a clinically significant difference in health status in patients with heart failure. We evaluated how the magnitude of change relates to subsequent c ... Full text Link to item Cite

Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study.

Journal article JAMA Cardiol · January 1, 2019 IMPORTANCE: African Americans have a higher burden of heart failure (HF) risk factors and clinical HF than other racial/ethnic groups. However, the factors underlying the transition from at-risk to clinical HF in African Americans are not well understood. ... Full text Link to item Cite

Death: The Simple Clinical Trial Endpoint.

Journal article Stud Health Technol Inform · 2019 Death, as a biological phenomenon, is well understood and a commonly employed endpoint for clinical trials. However, death identification and adjudication may be difficult for pragmatic clinical trials (PCT) that rely upon electronic health record and pati ... Link to item Cite

All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System.

Journal article Am J Ther · 2019 BACKGROUND: Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, government-man ... Full text Link to item Cite

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.

Journal article JAMA · December 4, 2018 IMPORTANCE: Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function. OBJECTIVE: ... Full text Link to item Cite

Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial.

Journal article JACC Heart Fail · December 2018 OBJECTIVES: This study sought to evaluate the influence of baseline physical activity (PA) on responses to aerobic exercise training and clinical events in outpatients with chronic systolic heart failure (HF) from the multicenter HF-ACTION (Exercise Traini ... Full text Link to item Cite

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Journal article N Engl J Med · November 29, 2018 BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), wou ... Full text Link to item Cite

Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Journal article Am J Cardiol · November 1, 2018 We aimed to study whether jugular venous distension (JVD) and peripheral edema were associated with worse outcomes in patients with acute heart failure in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial. Of 7,14 ... Full text Link to item Cite

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.

Journal article Am Heart J · November 2018 BACKGROUND: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical e ... Full text Link to item Cite

Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients.

Journal article J Palliat Med · November 2018 Heart failure (HF) is an increasingly prevalent condition with a very high symptom burden. To address challenges faced by palliative care clinicians, we assembled a team of experts to provide high-yield tips for the management of these patients. Prognosis ... Full text Link to item Cite

Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks.

Journal article Circ Heart Fail · November 2018 BACKGROUND: Obesity is highly prevalent among blacks and is associated with a greater risk of heart failure (HF). However, the contribution of regional adiposity depots such as visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue toward ... Full text Link to item Cite

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Journal article J Am Heart Assoc · October 2, 2018 Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patients ... Full text Open Access Link to item Cite

Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.

Journal article Am Heart J · October 2018 INTRODUCTION: Worsening renal function (WRF) can occur throughout a hospitalization for acute heart failure (HF). However, decongestion can be measured in different ways and the prognostic implications of WRF in the setting of different measures of deconge ... Full text Link to item Cite

Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus.

Journal article JACC Heart Fail · October 2018 There is increasing recognition of the relationship between diabetes and heart failure (HF). Comorbid diabetes is associated with worse outcomes in patients with HF, and death from HF forms a large burden of mortality among patients with diabetes and ather ... Full text Link to item Cite

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Journal article JACC Heart Fail · October 2018 OBJECTIVES: This study sought to evaluate and contribute to the limited data on U.S. hospital practice patterns with respect to respiratory vaccination in patients hospitalized with heart failure (HF). BACKGROUND: Respiratory infection is a major driver of ... Full text Link to item Cite

Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.

Journal article Circ Heart Fail · October 2018 BACKGROUND: Stroke prophylaxis in patients with atrial fibrillation (AF) and heart failure (HF) in the era of direct oral anticoagulants is not well characterized. Using data from American Heart Association Get With The Guidelines-AFIB, we sought to evalua ... Full text Link to item Cite

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Journal article Circ Cardiovasc Qual Outcomes · October 2018 BACKGROUND: Globalization of clinical trials fosters inclusion of higher and lower income countries, but the influence of enrolling country income level on heart failure trial performance is unclear. This study sought to evaluate associations between enrol ... Full text Link to item Cite

Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction.

Journal article Am J Cardiol · September 15, 2018 Patients with chronic kidney disease (CKD) and/or end-stage renal disease are less active and experience significant functional limitations. The impact of a structured aerobic exercise intervention on outcomes in ambulatory heart failure (HF) patients with ... Full text Link to item Cite

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Journal article Circulation · September 4, 2018 With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging, and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal tren ... Full text Link to item Cite

Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization.

Journal article J Card Fail · September 2018 AIMS: To explore the association of changes in weight and fluid during treatment for acute heart failure (AHF) with clinical endpoints. METHODS AND RESULTS: Weight and net fluid changes recorded at 72-96 hours in 708 AHF patients enrolled in Diuretic Optim ... Full text Link to item Cite

Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.

Journal article Eur J Heart Fail · September 2018 AIM: To describe differences in patient characteristics and outcomes by ethnicity in patients with diabetes mellitus (DM) and heart failure (HF) with reduced ejection fraction (HFrEF, ejection fraction ≤35%) in a multi-ethnic cohort. METHODS AND RESULTS: P ... Full text Link to item Cite

The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.

Journal article Clin Cardiol · September 2018 Heart failure (HF) and type 2 diabetes mellitus (T2DM) are two global pandemics, affecting over 25 and 420 million people, respectively. The prevalence of comorbid HF and T2DM is rising, and the prognosis remains poor. One central area of overlap of these ... Full text Link to item Cite

Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study.

Journal article J Clin Apher · August 2018 INTRODUCTION: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation. METHODS: In a retrospective study of patients who underwent cardiac transplantation at Duke University Medical ... Full text Open Access Link to item Cite

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Journal article Am J Cardiol · July 15, 2018 Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD). Contemporary estimates of SCD risk after hospitalization for heart failure are limited. We describe t ... Full text Link to item Cite

Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study).

Journal article Am J Cardiol · July 15, 2018 Conflicting data exist regarding the associations of early repolarization (ER) with electrocardiogram (ECG) and clinical outcomes in blacks. We examined the association of ER defined by J point elevation (JPE) and all-cause mortality, and heart failure (HF ... Full text Link to item Cite

Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.

Journal article Clin Cardiol · July 2018 BACKGROUND: Heart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fr ... Full text Link to item Cite

Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study.

Journal article Circulation · June 12, 2018 BACKGROUND: Cigarette smoking has been linked with several factors associated with cardiac dysfunction. We hypothesized that cigarette smoking is associated with left ventricular (LV) structure and function, and incident heart failure (HF) hospitalization. ... Full text Link to item Cite

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal article J Am Coll Cardiol · June 12, 2018 BACKGROUND: Surveys of patients with cardiovascular disease have suggested that "home-time"-being alive and out of any health care institution-is a prioritized outcome. This novel measure has not been studied among patients with heart failure (HF). OBJECTI ... Full text Link to item Cite

The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.

Journal article Eur J Heart Fail · June 2018 Although traditional renin-angiotensin system antagonists including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of cardiovascular disease (CVD), the pivotal PARADIGM-HF trial demonstrated tha ... Full text Link to item Cite

Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.

Journal article Am Heart J · June 2018 BACKGROUND: On May 20, 2016, US professional organizations in cardiology published joint treatment guidelines recommending the use of angiotensin-receptor neprilysin inhibitor (ARNI) for eligible patients with heart failure with reduced ejection fraction ( ... Full text Link to item Cite

Traveling the Interstices of Data Sharing.

Journal article JACC Heart Fail · June 2018 Full text Link to item Cite

Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study.

Journal article Am Heart J · June 2018 BACKGROUND: Non-adherence to medications is common and leads to suboptimal outcomes. Non-adherence can be intentional (e.g., deciding to skip dosages) or unintentional (e.g., forgetting), yet few studies have distinguished these reasons. An improved unders ... Full text Link to item Cite

Hyperkalemia in Heart Failure: Probably Not O"K".

Journal article J Am Heart Assoc · May 22, 2018 Full text Link to item Cite

Trends and outcomes of cardiac transplantation from donors dying of drug intoxication.

Journal article Am Heart J · May 2018 BACKGROUND: Deaths from drug intoxication have increased in the United States but outcomes of recipients of orthotopic heart transplantation (OHT) from these donors are not well characterized. METHODS: We performed a retrospective analysis of the United Ne ... Full text Link to item Cite

Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Journal article Am Heart J · May 2018 BACKGROUND: Despite more than 200 years of clinical experience and a pivotal trial, recently published research has called into question the safety and efficacy of digoxin therapy in heart failure (HF). METHODS: HF-ACTION (ClinicalTrials.gov Number: NCT000 ... Full text Link to item Cite

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Journal article JACC Heart Fail · April 2018 OBJECTIVES: As the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the r ... Full text Link to item Cite

Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

Journal article JAMA Cardiol · March 1, 2018 IMPORTANCE: Hospitalizations for worsening heart failure (WHF) represent an enormous public health and financial burden, with physicians, health systems, and payers placing increasing emphasis on hospitalization prevention. In addition, maximizing time out ... Full text Link to item Cite

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal article J Am Heart Assoc · February 3, 2018 BACKGROUND: Higher body mass index (BMI) is associated with lower circulating levels of N-terminal-pro-b-type natriuretic peptide (NT-proBNP). The Interaction between BMI and NT-proBNP with respect to clinical outcomes is not well characterized in patients ... Full text Link to item Cite

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Journal article Eur J Heart Fail · February 2018 AIMS: Patients hospitalized for heart failure (HF) are at high risk for 30-day readmission. This study sought to examine the timings and causes of readmission within 30 days of an HF hospitalization. METHODS AND RESULTS: Timing and cause of readmission in ... Full text Link to item Cite

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Journal article Lancet Diabetes Endocrinol · February 2018 BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We ... Full text Link to item Cite

Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support.

Journal article ASAIO J · 2018 Frailty and heart failure share common pathways with symptoms that often coexist. Assessment of frailty may inform patient selection for left ventricular assist device (LVAD) therapy. Using Interagency Registry for Mechanically Assisted Circulatory Support ... Full text Link to item Cite

Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial.

Journal article Contemp Clin Trials · January 2018 INTRODUCTION: Acute decompensated heart failure (ADHF) is the leading cause of hospitalization in older adults. Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial is a multi-site clinical trial to determine if physical rehabilita ... Full text Link to item Cite

Smartphone ECG for evaluation of ST-segment elevation myocardial infarction (STEMI): Design of the ST LEUIS International Multicenter Study.

Journal article J Electrocardiol · 2018 In patients experiencing an ST-elevation myocardial infarction (STEMI), rapid diagnosis and immediate access to reperfusion therapy leads to optimal clinical outcomes. The rate-limiting step in STEMI diagnosis is the availability and performance of a 12-le ... Full text Open Access Link to item Cite

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Journal article N Engl J Med · September 28, 2017 BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, ... Full text Open Access Link to item Cite

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

Journal article JAMA Cardiol · September 1, 2017 IMPORTANCE: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse ne ... Full text Link to item Cite

Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure.

Journal article Am Heart J · September 2017 BACKGROUND: Assessing health-related quality of life (HRQoL) in patients with heart failure (HF) is an important goal of clinical care and HF research. We sought to investigate ethnic differences in perceived HRQoL and its association with mortality among ... Full text Link to item Cite

Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries.

Journal article Epidemiology · September 2017 BACKGROUND: The Jackson Heart Study (JHS) assesses cardiovascular disease risk factors among African Americans in Jackson, Mississippi. Whether characteristics of JHS participants differ from those of a broader African American population are unknown. METH ... Full text Link to item Cite

Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

Journal article Eur J Heart Fail · August 2017 The aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits ... Full text Link to item Cite

Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial.

Journal article J Am Coll Cardiol · July 18, 2017 BACKGROUND: Advanced heart failure (HF) is characterized by high morbidity and mortality. Conventional therapy may not sufficiently reduce patient suffering and maximize quality of life. OBJECTIVES: The authors investigated whether an interdisciplinary pal ... Full text Link to item Cite

Palliative Care in Heart Failure The PAL-HF Randomized, Controlled Clinical Trial

Journal article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · July 18, 2017 Link to item Cite

Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).

Journal article Am J Cardiol · July 1, 2017 Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post hoc analysis was performed using pooled data from the Diuretic Optimization Strategies Evaluation in ... Full text Link to item Cite

Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.

Journal article JACC Heart Fail · July 2017 OBJECTIVES: In this study, the authors used biomarker profiles to characterize differences between patients with acute heart failure with a midrange ejection fraction (HFmrEF) and compare them with patients with a reduced (heart failure with a reduced ejec ... Full text Link to item Cite

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Journal article J Am Coll Cardiol · June 27, 2017 BACKGROUND: It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivors differ from those with more recent HF diagnoses. OBJECTIVES: The goal of this study was to evaluate the influence of HF chronicity on ac ... Full text Link to item Cite

Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular Disease).

Journal article Am J Cardiol · June 1, 2017 Angina pectoris (AP) has different prognostic implications in various populations. Patients with diabetes mellitus (DM) may experience neuropathy such that AP may not be perceived in the setting of coronary artery disease (CAD). The prognostic utility of A ... Full text Link to item Cite

Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study.

Journal article Circ Heart Fail · June 2017 BACKGROUND: African Americans develop chronic kidney disease and pulmonary hypertension (PH) at disproportionately high rates. Little is known whether PH heightens the risk of heart failure (HF) admission or mortality among chronic kidney disease patients, ... Full text Link to item Cite

Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.

Journal article JAMA Cardiol · June 1, 2017 IMPORTANCE: Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our kn ... Full text Link to item Cite

Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?

Journal article J Am Coll Cardiol · May 23, 2017 Heart failure (HF) is associated with significant morbidity and mortality. Although initially thought to be harmful in HF, beta-adrenergic blockers (β-blockers) have consistently been shown to reduce mortality and HF hospitalization in chronic HF with redu ... Full text Link to item Cite

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Journal article Am Heart J · May 2017 BACKGROUND: EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) ... Full text Link to item Cite

Acute Heart Failure: Alternatives to Hospitalization.

Journal article JACC Heart Fail · May 2017 Acute heart failure (HF) is a major public health problem with substantial associated economic costs. Because most patients who present to hospitals are admitted irrespective of their level of risk, novel approaches to manage acute HF are needed, such as t ... Full text Link to item Cite

The burden of proof: The current state of atrial fibrillation prevention and treatment trials.

Journal article Heart Rhythm · May 2017 Atrial fibrillation (AF) is an age-related arrhythmia of enormous socioeconomic significance. In recent years, our understanding of the basic mechanisms that initiate and perpetuate AF has evolved rapidly, catheter ablation of AF has progressed from concep ... Full text Link to item Cite

Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study.

Journal article Mayo Clin Proc · May 2017 OBJECTIVE: To assess the associations of perceived discrimination and cardiovascular (CV) outcomes in African Americans (AAs) in the Jackson Heart Study. PATIENTS AND METHODS: In 5085 AAs free of clinical CV disease at baseline enrolled in the Jackson Hear ... Full text Link to item Cite

Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation.

Journal article J Am Coll Cardiol · April 4, 2017 BACKGROUND: The safety and efficacy of aerobic exercise in heart failure (HF) patients with atrial fibrillation (AF) has not been well evaluated. OBJECTIVES: This study examined whether outcomes with exercise training in HF vary according to AF status. MET ... Full text Link to item Cite

Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.

Journal article Am Heart J · April 2017 BACKGROUND: Although aerobic exercise improves quality of life as assessed by a disease-specific instrument in ambulatory HF patients with a reduced ejection fraction (EF), the impact of an exercise intervention on general health status has not been previo ... Full text Link to item Cite

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).

Journal article JACC Heart Fail · April 2017 OBJECTIVES: The aim of this study was to assess the prevalence and variation in angiotensin receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The U.S. Food ... Full text Link to item Cite

Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.

Journal article J Am Coll Cardiol · March 21, 2017 BACKGROUND: The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, potentially facilitating decongestion and improving the clinical course of patients with acute heart failure (AHF). OBJECTIVES: The TACTICS- ... Full text Link to item Cite

Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction.

Journal article J Am Heart Assoc · March 20, 2017 BACKGROUND: Prolonged QRS duration is associated with increased mortality among heart failure patients, but race or sex differences in QRS duration and associated effect on outcomes are unknown. METHODS AND RESULTS: We investigated QRS duration and morphol ... Full text Open Access Link to item Cite

Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.

Journal article Am Heart J · March 2017 BACKGROUND: Acute decompensated heart failure (ADHF) is a leading cause of hospitalization in older persons in the United States. Reduced physical function and frailty are major determinants of adverse outcomes in older patients with hospitalized ADHF. How ... Full text Link to item Cite

Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.

Journal article JACC Heart Fail · March 2017 Heart failure (HF) is a chronic syndrome characterized by acute exacerbations. There is significant overlap between respiratory infections and exacerbation of underlying HF. Vaccination against respiratory infections in patients with HF could serve as a po ... Full text Link to item Cite

Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Journal article J Heart Lung Transplant · February 2017 BACKGROUND: Pre-transplant amiodarone use has been postulated as a risk factor for morbidity and mortality after orthotopic heart transplantation (OHT). We assessed pre-OHT amiodarone use and tested the hypothesis that it is associated with impaired post-O ... Full text Link to item Cite

Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.

Journal article Eur J Heart Fail · February 2017 AIMS: Heart failure (HF) can be associated with a higher resting heart rate (HR), and an elevated HR is associated with adverse long-term events. However, the mechanistic and causal role of HR in HF is unclear. This study aimed to investigate changes in HR ... Full text Link to item Cite

Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study.

Journal article JAMA Cardiol · February 1, 2017 IMPORTANCE: Increased resting heart rate is associated with worse outcomes in studies of mostly white populations, but its significance is not well established in African Americans persons whose cardiac comorbidities and structural abnormalities differ. OB ... Full text Link to item Cite

Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.

Journal article Curr Heart Fail Rep · February 2017 Heart failure is a global pandemic and there has been a growing effort to enroll patients from different geographical regions in randomized controlled trials. In this review, we examined regional variation in both patient characteristics and outcomes among ... Full text Link to item Cite

Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.

Journal article Clin Cardiol · January 2017 BACKGROUND: Several diabetes mellitus (DM) therapies are associated with worse heart failure (HF) outcomes, yet limited data exist characterizing routine DM management based on HF status. HYPOTHESIS: DM medications prescribed for patients with HF will diff ... Full text Link to item Cite

Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data.

Journal article ASAIO J · 2017 Selection is a key determinant of clinical outcomes after left ventricular assist device (LVAD) placement in patients with end-stage heart failure. The HeartMate II risk score (HMRS) has been proposed to facilitate risk stratification and patient selection ... Full text Link to item Cite

Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes.

Journal article Am Heart J · January 2017 BACKGROUND: Prognosis in patients with heart failure (HF) is commonly assessed based on clinical characteristics. The association between partner status and socioeconomic status (SES) and outcomes in chronic HF requires further study. METHODS: We performed ... Full text Link to item Cite

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Journal article JACC Heart Fail · January 2017 OBJECTIVES: This study sought to examine the relationships between in-hospital and post-discharge body weight changes and outcomes among patients hospitalized for acute heart failure (AHF). BACKGROUND: Body weight changes during and after hospitalization f ... Full text Link to item Cite

Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study.

Journal article J Am Heart Assoc · December 7, 2016 BACKGROUND: In 2014, new hypertension guidelines liberalized blood pressure goals for persons 60 years and older. Little is known about the implications for blacks. METHODS AND RESULTS: Using data from 2000 through 2011 for 5280 participants in the Jackson ... Full text Link to item Cite

Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score.

Journal article J Card Fail · November 2016 OBJECTIVE: To characterize a novel "worst"-symptom visual analogue scale (WS-VAS) versus the traditional dyspnea visual analogue scale (DVAS) in an acute heart failure (AHF) trial. BACKGROUND: AHF trials assess symptom relief as a pivotal endpoint with the ... Full text Link to item Cite

Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF.

Journal article J Card Fail · November 2016 BACKGROUND: Hypoalbuminemia is common in patients with chronic heart failure and, as a marker of disease severity, is associated with an adverse prognosis. Whether hypoalbuminemia contributes to (or is associated with) worse outcomes in acute heart failure ... Full text Link to item Cite

Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.

Journal article J Card Fail · November 2016 BACKGROUND: Readmission or death after heart failure (HF) hospitalization is a consequential and closely scrutinized outcome, but risk factors may vary by population. We characterized the risk factors for post-discharge readmission/death in subjects treate ... Full text Link to item Cite

Acute heart failure in the young: Clinical characteristics and biomarker profiles.

Journal article Int J Cardiol · October 15, 2016 BACKGROUND: Young patients (<50years) exhibit specific characteristics in chronic heart failure (HF), but their phenotype in acute heart failure (AHF) is not well described. METHODS AND RESULTS: 2033 patients of the PROTECT trial were divided into two grou ... Full text Link to item Cite

Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Journal article Am J Cardiol · October 15, 2016 Angina pectoris (AP) is associated with worse outcomes in heart failure (HF). We investigated the association of AP with health-related quality of life (HRQoL), exercise capacity, and clinical outcomes and its interaction with exercise training in an HF po ... Full text Link to item Cite

Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes.

Journal article J Card Fail · September 2016 BACKGROUND: Though commonly noted in clinical practice, it is unknown if decongestion in acute heart failure (AHF) results in increased serum bicarbonate. METHODS AND RESULTS: For 678 AHF patients in the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials, we assess ... Full text Link to item Cite

Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices.

Journal article Am J Cardiol · September 1, 2016 Within the last decade, advancements in left ventricular assist device therapy have allowed patients with end-stage heart failure (HF) to live longer and with better quality of life. Like other life-saving interventions, however, there remains the risk of ... Full text Link to item Cite

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Journal article Circ Heart Fail · September 2016 BACKGROUND: Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear. METHODS AND RESULTS: We assessed the impact of varyi ... Full text Link to item Cite

The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study.

Journal article J Card Fail · August 2016 BACKGROUND: Higher rates of obesity and heart failure have been observed in African Americans, but associations with mortality are not well-described. We examined intermediate and long-term clinical implications of obesity in African Americans and associat ... Full text Link to item Cite

Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.

Journal article JACC Heart Fail · August 2016 OBJECTIVES: The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response. BACKGROUND: Recent data suggest that statins may attenuate ET response, but limited data exist in patients with heart failur ... Full text Link to item Cite

Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE).

Journal article Am Heart J · August 2016 BACKGROUND: A subset of patients hospitalized with acute heart failure experiences in-hospital worsening heart failure, defined as persistent or worsening signs or symptoms requiring an escalation of therapy. METHODS: We analyzed data from the Acute Decomp ... Full text Link to item Cite

Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.

Journal article Circ Heart Fail · August 2016 BACKGROUND: In-hospital worsening heart failure (WHF) is an important event that has inconsistent definitions used across trials. We used data from 2 acute heart failure (HF) trials from the National Institutes of Health HF Network, DOSE (Diuretic Optimiza ... Full text Link to item Cite

Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial.

Journal article J Card Fail · July 2016 BACKGROUND: In HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), exercise training improved functional capacity in heart failure with reduced ejection fraction (HFrEF). Previous studies have suggested that diabetes ... Full text Link to item Cite

Neural modulation for hypertension and heart failure.

Journal article Int J Cardiol · July 1, 2016 Hypertension (HTN) and heart failure (HF) have a significant global impact on health, and lead to increased morbidity and mortality. Despite recent advances in pharmacologic and device therapy for these conditions, there is a need for additional treatment ... Full text Link to item Cite

Cardiorenal Interactions.

Journal article Heart Fail Clin · July 2016 Recently, there has been increased appreciation of the identification and management of comorbidities in heart failure patients, and for therapies targeting conventional heart failure signs and symptoms. Renal dysfunction is common in patients with heart f ... Full text Link to item Cite

Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials.

Journal article Eur J Heart Fail · June 2016 AIMS: It remains unclear if early administration of i.v. nesiritide in patients hospitalized with acute heart failure (AHF) is associated with improved clinical outcomes. METHODS AND RESULTS: We analysed data from 7007 patients enrolled in ASCEND-HF to exa ... Full text Link to item Cite

Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial).

Journal article Am J Cardiol · June 1, 2016 A growing number of countries and geographical regions are involved in major clinical trials. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure is the largest trial in acutely decompensated heart failure (HF) with patients ... Full text Link to item Cite

Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Journal article JACC Heart Fail · June 2016 Heart failure (HF) is a major and increasing global public health problem. In Asia, aging populations and recent increases in cardiovascular risk factors have contributed to a particularly high burden of HF, with outcomes that are poorer than those in the ... Full text Link to item Cite

Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.

Journal article Circ Heart Fail · May 2016 BACKGROUND: Dyspnea is the most common symptom among hospitalized patients with heart failure and represents a therapeutic target. However, the association between short-term dyspnea relief and postdischarge clinical outcomes and health-related quality of ... Full text Link to item Cite

Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction.

Journal article J Thromb Thrombolysis · April 2016 We aimed to characterize the independent predictors of LVT following STEMI and the association with outcomes. The clinical predictors of left ventricular thrombus (LVT) formation after ST-segment elevation myocardial infarction (STEMI) are not well-defined ... Full text Link to item Cite

Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF.

Journal article Eur J Heart Fail · April 2016 AIMS: We aimed to characterize abnormal liver function tests in patients with heart failure (HF), as they are commonly encountered yet poorly defined. METHODS AND RESULTS: We used data from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in ... Full text Link to item Cite

Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.

Journal article Am J Cardiol · April 1, 2016 Serum osmolality may fluctuate with neurohormonal activation and in response to certain therapeutics in patients with heart failure (HF). The clinical relevance of osmolality in patients with HF has not been defined. In this post hoc analysis of the Effica ... Full text Link to item Cite

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

Journal article Am Heart J · April 2016 Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide-1 receptor agonist, which can improve glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). The EXena ... Full text Link to item Cite

Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs.

Journal article Am J Cardiol · March 15, 2016 There are limited data describing outcomes associated with an elevated heart rate in patients with heart failure with reduced ejection fraction (HFrEF) in routine clinical practice. We identified patients with HFrEF at Duke University Hospital undergoing e ... Full text Link to item Cite

Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population.

Journal article J Heart Lung Transplant · March 2016 BACKGROUND: With increasing age of patients with heart failure, it is important to understand the potential role for orthotopic heart transplant (OHT) in elderly patients. We examined recipient and donor characteristics and long-term outcomes of older reci ... Full text Link to item Cite

The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Journal article Eur J Heart Fail · March 2016 AIMS: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND RESULTS: A post-hoc analysis was performed of the ASCEND-HF trial. Th ... Full text Link to item Cite

Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?

Journal article J Card Fail · March 2016 BACKGROUND: Patients with advanced heart failure may continue for prolonged times with persistent hemodynamic abnormalities; intermediate- and long-term outcomes of these patients are unknown. METHODS AND RESULTS: We used ESCAPE (Evaluation Study of Conges ... Full text Link to item Cite

Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry.

Journal article Am Heart J · March 2016 BACKGROUND: Elevated heart rate of ≥70 beats/min despite β-blocker use may represent a new treatment target in patients in sinus rhythm with heart failure with reduced ejection fraction. However, little is known about the proportion of patients with elevat ... Full text Link to item Cite

Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds.

Journal article Circulation · March 1, 2016 Randomized, clinical trials are commonly regarded as the highest level of evidence to support clinical decisions. Good Clinical Practice guidelines have been constructed to provide an ethical and scientific quality standard for trials that involve human su ... Full text Link to item Cite

Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).

Journal article Am J Cardiol · February 1, 2016 Furosemide is the most commonly used loop diuretic in patients with heart failure (HF) despite data suggesting potential pharmacologic and antifibrotic benefits with torsemide. We investigated patients with HF in Acute Study of Clinical Effectiveness of Ne ... Full text Link to item Cite

Comorbidities in Heart Failure: Are There Gender Differences?

Journal article Curr Heart Fail Rep · February 2016 Compared to men, women with heart failure (HF) are often older, smoke less, and have more preserved ejection fraction (EF) and hypertensive HF rather than HF of ischemic etiology. Gender-stratified outcomes on comorbidities data in HF are scarce. Women hav ... Full text Link to item Cite

Pathophysiology and clinical evaluation of acute heart failure.

Journal article Nat Rev Cardiol · January 2016 Acute heart failure (AHF) is a complex syndrome characterized by worsening heart failure (HF) symptoms that requires escalation of therapy. Intrinsic cardiac abnormalities and comorbid conditions, including lung and renal disease, and sleep-disordered brea ... Full text Link to item Cite

Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.

Journal article Eur J Heart Fail · December 2015 AIMS: Troponin elevation is common in acute heart failure (AHF) and may be useful for prognostication; however, available data are mixed and many previous studies used older, less sensitive assays. We examined the association between serial measurements of ... Full text Link to item Cite

Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.

Journal article Am Heart J · December 2015 BACKGROUND: Patients hospitalized with acute heart failure may experience worsening symptoms requiring escalation of therapy. In-hospital worsening heart failure is associated with worse in-hospital and postdischarge outcomes, but associations between the ... Full text Link to item Cite

Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).

Journal article Circ Heart Fail · November 2015 BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients. We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes. METHOD ... Full text Link to item Cite

Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.

Journal article Am J Cardiol · October 15, 2015 Acute heart failure (AHF) is a complex syndrome with presentations ranging from hypotensive cardiogenic shock to hypertensive emergency with pulmonary edema. Most patients with AHF present with worsening of chronic HF signs and symptoms over days to weeks, ... Full text Link to item Cite

Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations.

Journal article Heart Fail Clin · October 2015 Hospitalized heart failure (HHF) patients carry a prognosis comparable to many cancers and constitute more than 1 million hospital admissions annually in the United States. To date, North Americans have comprised a minority of those included in prior hospi ... Full text Link to item Cite

Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study.

Journal article Heart Fail Clin · October 2015 Although the prognosis of ambulatory heart failure (HF) has improved dramatically there have been few advances in the management of acute HF (AHF). Despite regional differences in patient characteristics, background therapy, and event rates, AHF clinical t ... Full text Open Access Link to item Cite

End-of-life Heart Failure Care in the United States.

Journal article Heart Fail Clin · October 2015 Heart failure (HF) is increasingly common in the United States and is associated with a high degree of morbidity and mortality. As patients approach the end of life there is a significant increase in health care resource use. Patients with end-stage HF hav ... Full text Link to item Cite

Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.

Journal article J Card Fail · September 2015 Heart failure (HF) is an increasingly common syndrome associated with high mortality and economic burden, and there has been a paucity over the past decade of new pharmacotherapies that improve outcomes. However, recent data from a large randomized control ... Full text Open Access Link to item Cite

Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.

Journal article Circ Heart Fail · September 2015 Congestion is a primary reason for hospitalization in patients with acute heart failure (AHF). Despite inpatient diuretics and vasodilators targeting decongestion, persistent congestion is present in many AHF patients at discharge and more severe congestio ... Full text Link to item Cite

Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Journal article Future Cardiol · September 2015 AIM: The authors assessed the comparative effectiveness of torsemide versus furosemide in the PROTECT trial. METHODS: The authors assessed the relationship between loop diuretic at discharge and death or cardiovascular/renal hospitalization within 30 days, ... Full text Link to item Cite

Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).

Journal article Am Heart J · August 2015 BACKGROUND: Despite initial in-hospital treatment of acute heart failure (HF), some patients experience worsening HF (WHF). There are limited data about the outcomes and characteristics of patients who experience in-hospital WHF. METHODS AND RESULTS: We as ... Full text Link to item Cite

Atherosclerosis: Recent trials, new targets and future directions.

Journal article Int J Cardiol · August 1, 2015 Mortality from cardiovascular diseases (CVD) represents the primary cause of death worldwide. Prevention or treatment of atherosclerosis and its clinical sequelae is a central goal in the management of patients with established vascular disease or those at ... Full text Link to item Cite

Site selection for heart failure clinical trials in the USA.

Journal article Heart Fail Rev · July 2015 There are more than 1 million primary hospitalizations for heart failure (HF) annually in the USA alone, and post-discharge outcomes remain persistently poor despite available therapies and quality improvement initiatives. Recent international randomized c ... Full text Link to item Cite

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Journal article Circ Heart Fail · July 2015 BACKGROUND: Congestion is the most frequent cause for hospitalization in acute decompensated heart failure. Although decongestion is a major goal of acute therapy, it is unclear how the clinical components of congestion (eg, peripheral edema, orthopnea) co ... Full text Open Access Link to item Cite

Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial.

Journal article Eur J Heart Fail · July 2015 BACKGROUND: Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is ... Full text Link to item Cite

Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training.

Journal article Circ Heart Fail · May 2015 BACKGROUND: Although studies have shown that depression is associated with worse outcomes in patients with heart failure, most studies have been in white patients. The impact of depression on outcomes in blacks with heart failure has not been studied. METH ... Full text Link to item Cite

Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Journal article J Cardiovasc Pharmacol · May 2015 Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hos ... Full text Open Access Link to item Cite

Patient selection in heart failure with preserved ejection fraction clinical trials.

Journal article J Am Coll Cardiol · April 28, 2015 Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved left ventricu ... Full text Link to item Cite

Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study.

Journal article Circ Heart Fail · March 2015 BACKGROUND: QRS prolongation is associated with adverse outcomes in mostly white populations, but its clinical significance is not well established for other groups. We investigated the association between QRS duration and mortality in African Americans. M ... Full text Open Access Link to item Cite

Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.

Journal article Am Heart J · March 2015 Advances in medical therapies leading to improved patient outcomes are in large part related to successful conduct of clinical trials that offer critical information regarding the efficacy and safety of novel interventions. The conduct of clinical trials i ... Full text Link to item Cite

A reappraisal of loop diuretic choice in heart failure patients.

Journal article Am Heart J · March 2015 The health and economic burden of heart failure is significant and continues to grow each year. Loop diuretics are an integral part of symptom management in heart failure. Furosemide is used disproportionately compared with other loop diuretics, and there ... Full text Link to item Cite

Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.

Journal article JACC Heart Fail · February 2015 OBJECTIVES: The purpose of this study was to assess the relationship between biomarkers of renin-angiotensin-aldosterone system (RAAS) activation and decongestion strategies, worsening renal function, and clinical outcomes. BACKGROUND: High-dose diuretic t ... Full text Open Access Link to item Cite

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.

Journal article JACC Heart Fail · February 2015 The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM) continues to increase with the general aging of the population. In patients with chronic HF, prevalence of DM is 24% compared with 40% in those hospitalized with wors ... Full text Link to item Cite

Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction.

Journal article Eur J Heart Fail · February 2015 Cardiac resynchronization therapy is beneficial in heart failure patients with LVEF ≤35% and electrical dyssynchrony. However, its effects among patients with less severe LV dysfunction have not been established. Recent post-hoc analyses of landmark CRT tr ... Full text Link to item Cite

D-Dimer elevation and adverse outcomes.

Journal article J Thromb Thrombolysis · January 2015 D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VT ... Full text Open Access Link to item Cite

Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial.

Journal article Eur J Heart Fail · January 2015 AIMS: Previous heart failure (HF) trials suggested that age influences patient characteristics and outcome; however, under-representation of elderly patients has limited characterization of this cohort. Whether standard prognostic variables have differenti ... Full text Link to item Cite

Relation of dyspnea severity on admission for acute heart failure with outcomes and costs.

Journal article Am J Cardiol · January 1, 2015 Hospitalization for heart failure (HF) is frequently related to dyspnea, yet associations among dyspnea severity, outcomes, and health care costs are unknown. The aim of this study was to describe the characteristics of patients hospitalized for acute HF b ... Full text Link to item Cite

Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.

Journal article Expert Rev Cardiovasc Ther · 2015 Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being disch ... Full text Link to item Cite

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction.

Journal article Open Heart · 2015 OBJECTIVE: Nuclear imaging data demonstrate that revascularisation leads to favourable effects on ischaemia burden and improved outcomes compared with medical therapy (MT). In patients with heart failure (HF), the effects of MT versus revascularisation on ... Full text Open Access Link to item Cite

d-Dimer elevation and adverse outcomes

Journal article Journal of Thrombosis and Thrombolysis · 2015 © 2014, The Author(s).d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of veno ... Full text Cite

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

Journal article J Am Coll Cardiol · December 2, 2014 Heart failure patients are classified by ejection fraction (EF) into distinct groups: heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF). Although patients with heart failure commonly have multipl ... Full text Link to item Cite

Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes.

Journal article Curr Heart Fail Rep · December 2014 Heart failure (HF) is a public health problem of global proportions afflicting more than 25 million patients worldwide. Despite stable or declining per capita hospitalization rates in the USA and several European countries, there are over one million hospi ... Full text Link to item Cite

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

Journal article Am J Cardiol · December 1, 2014 We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with specific focus on gender, race, and renal function base ... Full text Link to item Cite

The palliative care in heart failure trial: rationale and design.

Journal article Am Heart J · November 2014 BACKGROUND: The progressive nature of heart failure (HF) coupled with high mortality and poor quality of life mandates greater attention to palliative care as a routine component of advanced HF management. Limited evidence exists from randomized, controlle ... Full text Link to item Cite

Charting a roadmap for heart failure biomarker studies.

Journal article JACC Heart Fail · October 2014 Heart failure is a syndrome with a pathophysiological basis that can be traced to dysfunction in several interconnected molecular pathways. Identification of biomarkers of heart failure that allow measurement of the disease on a molecular level has resulte ... Full text Link to item Cite

Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Journal article Am J Cardiol · September 1, 2014 Despite the well-established benefits of mineralocorticoid receptor agonists (MRAs) in heart failure with reduced ejection fraction, safety concerns remain in patients with concomitant diabetes mellitus (DM) because of common renal and electrolyte abnormal ... Full text Link to item Cite

Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events.

Journal article Eur J Heart Fail · August 2014 AIMS: The impact of refractory angina pectoris (AP) in patients with ischaemic cardiomyopathy (ICM) is unknown. We investigated the characteristics and outcomes of ICM patients with persistent AP following cardiac catheterization. METHODS AND RESULTS: Pati ... Full text Link to item Cite

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

Journal article Am Heart J · August 2014 Recent international phase III clinical trials of novel therapies for hospitalized heart failure (HHF) have failed to improve the unacceptably high postdischarge event rate. These large studies have demonstrated notable geographic and site-specific variati ... Full text Link to item Cite

In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization.

Journal article J Am Heart Assoc · July 11, 2014 BACKGROUND: A subset of patients hospitalized with acute heart failure experiences worsening clinical status and requires escalation of therapy. Worsening heart failure is an end point in many clinical trials, but little is known about its prevalence in cl ... Full text Link to item Cite

International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.

Journal article Eur J Heart Fail · June 2014 AIMS: The implications of geographical variation are unknown following adjustment for hospital length of stay (LOS) in heart failure (HF) trials that included patients whether or not they had systolic dysfunction. We investigated regional differences in an ... Full text Link to item Cite

Decongestion in acute heart failure.

Journal article Eur J Heart Fail · May 2014 Congestion is a major reason for hospitalization in acute heart failure (HF). Therapeutic strategies to manage congestion include diuretics, vasodilators, ultrafiltration, vasopressin antagonists, mineralocorticoid receptor antagonists, and potentially als ... Full text Link to item Cite

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.

Journal article Circ Heart Fail · May 2014 BACKGROUND: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. METHODS AND ... Full text Link to item Cite

Sleep-disordered breathing in patients with heart failure.

Journal article Heart Fail Clin · April 2014 Sleep-disordered breathing (SDB) is prevalent in patients with heart failure, and is associated with increased morbidity and mortality. SDB is proinflammatory, with nocturnal oxygen desaturations and hypercapnia appearing to play a pivotal role in the deve ... Full text Link to item Cite

Patient selection for advanced heart failure therapy referral.

Journal article Crit Pathw Cardiol · March 2014 Despite advances in medical therapy for chronic heart failure (HF), advanced HF carries a dismal prognosis. Options such as transplantation and durable mechanical circulatory support have greatly improved outcomes for these patients, but their introduction ... Full text Link to item Cite

Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.

Journal article Heart Fail Rev · March 2014 There are over 1 million hospitalizations for heart failure (HF) annually in the United States alone, and a similar number has been reported in Europe. Recent clinical trials investigating novel therapies in patients with hospitalized HF (HHF) have been ne ... Full text Link to item Cite

Medical management of patients with continuous-flow left ventricular assist devices.

Journal article Curr Treat Options Cardiovasc Med · February 2014 The prevalence of patients living with advanced heart failure continues to rise. For a subset of these patients, continuous-flow left ventricular assist devices (LVADs) are a life-saving therapy. Given the efficacy and durability of contemporary LVAD devic ... Full text Link to item Cite

Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).

Journal article J Am Coll Cardiol · January 28, 2014 OBJECTIVES: This study investigated the characteristics and outcomes of patients with heart failure with preserved ejection fraction (HFpEF) and angina pectoris (AP). BACKGROUND: AP is a predictor of adverse events in patients with heart failure with reduc ... Full text Link to item Cite

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Journal article Eur J Heart Fail · December 2013 AIMS: Haemoconcentration has been studied as a marker of decongestion in patients with hospitalization for heart failure (HHF). We describe the relationship between haemoconcentration, worsening renal function, post-discharge outcomes, and clinical and lab ... Full text Link to item Cite

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Journal article Am J Cardiol · December 1, 2013 Serum magnesium levels may be impacted by neurohormonal activation, renal function, and diuretics. The clinical profile and prognostic significance of serum magnesium level concentration in patients hospitalized for heart failure (HF) with reduced ejection ... Full text Link to item Cite

Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research.

Journal article J Thromb Thrombolysis · November 2013 Contemporary cardiovascular research offers junior investigators the opportunity to explore the gamut of biomedical questions. Despite the recent reduction in the availability of funding mechanisms that have historically served as the primary pathways for ... Full text Link to item Cite

Learning from recent trials and shaping the future of acute heart failure trials.

Journal article Am Heart J · October 2013 The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine. As a resul ... Full text Link to item Cite

The past, present and future of renin-angiotensin aldosterone system inhibition.

Journal article Int J Cardiol · September 1, 2013 The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failu ... Full text Link to item Cite

Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).

Journal article Am Heart J · September 2013 BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established. We aimed to investigate the assoc ... Full text Link to item Cite

Heart failure in elderly patients: distinctive features and unresolved issues.

Journal article Eur J Heart Fail · July 2013 The prevalence of heart failure (HF) increases with age. While clinical trials suggest that contemporary evidence-based HF therapies have reduced morbidity and mortality, these trials largely excluded the elderly. Questions remain regarding the clinical ch ... Full text Link to item Cite

Noncardiac comorbidities and acute heart failure patients.

Journal article Heart Fail Clin · July 2013 The acute heart failure (AHF) population is a heterogeneous group with multiple interrelated noncardiovascular comorbidities. Chronic obstructive pulmonary disease, renal disease, diabetes, sleep apnea, and anemia affect the clinical characteristics and ou ... Full text Link to item Cite

Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.

Journal article Eur J Heart Fail · April 2013 AIMS: To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes. METHODS AND RESULTS: ASCEND-HF was a randomized trial of nesiritide vs. placebo in 7141 pa ... Full text Link to item Cite

Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).

Journal article Am J Cardiol · February 15, 2013 In patients with heart failure (HF) with chronic obstructive pulmonary disease (COPD), concerns exist regarding β blockers, particularly noncardioselective β blockers, precipitating bronchospasm or attenuating the benefit of inhaled β(2) agonists. The aim ... Full text Link to item Cite

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Journal article Am J Cardiol · February 15, 2013 Lower cholesterol levels are associated with worse outcomes in patients with chronic heart failure (HF) and have been shown to predict in-hospital mortality. The relation between lipid profile and postdischarge outcomes in patients hospitalized for worseni ... Full text Link to item Cite

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.

Journal article J Am Coll Cardiol · February 5, 2013 OBJECTIVES: The study investigated whether the number of participants enrolled per site in an acute heart failure trial is associated with participant characteristics and outcomes. BACKGROUND: Whether and how site enrollment volume affects clinical trials ... Full text Link to item Cite

Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION).

Journal article Am Heart J · February 2013 BACKGROUND: The aim of this study was to investigate the clinical characteristics, exercise training response, β-blocker selectivity, and outcomes in patients with heart failure (HF) and chronic obstructive pulmonary disease (COPD). METHODS: We performed a ... Full text Link to item Cite

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.

Journal article Am Heart J · February 2013 BACKGROUND: Systolic blood pressure (SBP) is related to the pathophysiologic development and progression of heart failure (HF) and is inversely associated with adverse outcomes during hospitalization for HF (HHF). The prognostic value of SBP after initiati ... Full text Link to item Cite

Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial.

Journal article Eur J Heart Fail · February 2013 AIMS: We evaluated the impact of diabetes mellitus (DM) and diabetic therapy on outcomes in patients with reduced ejection fraction (EF) after hospitalization for heart failure (HF). DM is prevalent in patients hospitalized with HF, yet inconclusive data e ... Full text Link to item Cite

Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.

Journal article Eur J Heart Fail · January 2013 AIMS: Data on the prognosis of heart failure (HF) patients with coronary artery disease (CAD) have been conflicting. We describe the clinical characteristics and mode-specific outcomes of HF patients with reduced ejection fraction (EF) and documented CAD i ... Full text Link to item Cite

Dysphagia in the setting of left ventricular assist device hemolysis.

Journal article ASAIO J · 2013 A 69-year-old man with advanced heart failure treated with a continuous-flow left ventricular assist device presented for evaluation of dark urine and severe dysphagia. Because of evidence of ongoing intravascular hemolysis with device dysfunction, there w ... Full text Link to item Cite

A crisis of the heart: an acute reversible cardiomyopathy bridged to recovery in a patient with Addison's disease.

Journal article ASAIO J · 2013 Primary adrenal insufficiency or Addison's disease is a rare disorder often difficult to diagnose on presentation by the nature of its associated nonspecific symptoms, such as nausea or weakness. Cardiovascular complications of the condition are usually li ... Full text Link to item Cite

Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).

Journal article Am J Cardiol · December 15, 2012 Women have traditionally been underrepresented in heart failure (HF) trials, and their baseline characteristics and outcomes after hospitalization for HF are unclear. We retrospectively analyzed the clinical characteristics and outcomes of patients accordi ... Full text Link to item Cite

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.

Journal article Am Heart J · December 2012 BACKGROUND: Heart failure (HF) complicated by atrial fibrillation/flutter (AF/AFL) is associated with worse outcomes. However, the clinical profile and outcomes of patients following hospitalization for HF with AF/AFL on initial electrocardiogram (ECG) has ... Full text Link to item Cite

Race, Exercise Training and Outcomes in Chronic Heart Failure

Journal article CIRCULATION · November 20, 2012 Link to item Cite

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.

Journal article Eur Heart J · November 2012 Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF-REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failur ... Full text Link to item Cite

Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Journal article Circ Heart Fail · November 2012 BACKGROUND: Low lymphocyte count has been shown to be an independent prognostic marker in heart failure (HF) in the outpatient setting. Limited data exist regarding whether relative lymphocyte count correlates with postdischarge outcomes in patients hospit ... Full text Link to item Cite

Reply

Journal article Journal of the American College of Cardiology · October 23, 2012 Full text Cite

Implications of geographical variation on clinical outcomes of cardiovascular trials.

Journal article Am Heart J · September 2012 Cardiovascular clinical trials are increasingly conducted globally as a means to reduce costs, expedite timelines, provide broad applicability, and satisfy regulatory authorities. Potential problems with trial globalization include regional differences in ... Full text Link to item Cite

The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.

Journal article J Card Fail · July 2012 BACKGROUND: Chronic obstructive pulmonary disease (COPD) is prevalent in heart failure (HF) patients, yet these patients are poorly characterized. We aimed to describe the characteristics and outcomes of patients with systolic dysfunction and COPD in a con ... Full text Link to item Cite

Diuretics and ultrafiltration in acute decompensated heart failure.

Journal article J Am Coll Cardiol · June 12, 2012 Congestion and volume overload are the hallmarks of acute decompensated heart failure (ADHF), and loop diuretics have historically been the cornerstone of treatment. The demonstrated efficacy of loop diuretics in managing congestion is balanced by the reco ... Full text Link to item Cite

The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction.

Journal article Eur J Heart Fail · June 2012 AIMS: In patients with acute heart failure (AHF), early worsening heart failure (WHF) predicts a significant proportion of post-discharge readmissions and mortality. We aimed to identify the predictors of 7-day heart failure events or death in patients hos ... Full text Link to item Cite

Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?

Journal article J Card Fail · May 2012 Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) commonly coexist, and patients with both diseases fare worse than those with either disease alone. Several factors may contribute to worse outcomes, including an increased burden o ... Full text Link to item Cite

Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease).

Journal article Am J Cardiol · May 1, 2012 Myocardial ischemic origin is a significant independent predictor of mortality in patients with heart failure (HF). The implications of angina pectoris (AP) in HF are less well characterized. The aim of this study was to compare the clinical characteristic ... Full text Link to item Cite

Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.

Journal article Eur J Heart Fail · April 2012 AIMS: Chronic obstructive pulmonary disease (COPD) is common in heart failure (HF) patients, yet the population is poorly characterized and associated with conflicting outcomes data. We aimed to evaluate the clinical characteristics and outcomes of HF pati ... Full text Link to item Cite

Cardiorenal syndrome clinical trial end points.

Journal article Heart Fail Clin · October 2011 Cardiorenal syndrome is a focus of interest in heart failure because of the substantial associated morbidity and mortality. Recent clinical trials of novel heart failure therapies targeting the interdependence of cardiac and renal dysfunction have failed t ... Full text Link to item Cite

Covariate adjustment in heart failure randomized controlled clinical trials: a case analysis of the HF-ACTION trial.

Journal article Heart Fail Clin · October 2011 Randomized controlled clinical trials are predominantly used to determine the benefit of a therapeutic intervention in patients with congestive heart failure (HF). These trials are commonly lengthy and expensive, and enroll patients with baseline imbalance ... Full text Link to item Cite

Epidemiology of cardiorenal syndrome.

Journal article Cardiol Clin · May 2011 The interdependence of cardiac and renal dysfunction has emerged as a focus of intense interest in heart failure management due to the substantial associated morbidity and mortality. Captured in the clinical entity known as cardiorenal syndrome, recent def ... Full text Link to item Cite

Natriuretic Peptide-guided therapy for heart failure.

Journal article Circ J · 2011 Chronic heart failure (HF) remains a major medical problem in the developed world, with rapidly rising prevalence, substantial morbidity, and high costs. The concept of titrating chronic HF therapies using physiologic markers, so called "biomarker guided t ... Full text Link to item Cite

Epidemiology of cardiorenal syndrome.

Journal article Heart Fail Clin · July 2010 The interdependence of cardiac and renal dysfunction has emerged as a focus of intense interest in heart failure management due to the substantial associated morbidity and mortality. Captured in the clinical entity known as cardiorenal syndrome, recent def ... Full text Link to item Cite